**Systematic literature review and network meta-analysis of pembrolizumab versus other interventions for previously untreated, unresectable or metastatic, microsatellite instability-high or mismatch repair deficient colorectal cancer**

**Supplementary Tables**

Table S1: Search strategy for Embase

Database: Embase 1974 to July 12, 2019

Search executed on July 15, 2019

|  |  |  |  |
| --- | --- | --- | --- |
| No. | Criteria | Strings | Hits |
| 1 | SIGN filter for clinical trials | Clinical Trial/ | 960,800 |
| 2 | Randomized Controlled Trial/ | 558,380 |
| 3 | controlled clinical trial/ | 464,023 |
| 4 | multicenter study/ | 221,201 |
| 5 | Phase 3 clinical trial/ | 40,735 |
| 6 | Phase 4 clinical trial/ | 3,473 |
| 7 | exp RANDOMIZATION/ | 83,369 |
| 8 | Single Blind Procedure/ | 35,752 |
| 9 | Double Blind Procedure/ | 162,673 |
| 10 | Crossover Procedure/ | 59,859 |
| 11 | PLACEBO/ | 337,644 |
| 12 | randomi?ed controlled trial$.tw. | 206,375 |
| 13 | rct.tw. | 33,023 |
| 14 | (random$ adj2 allocat$).tw. | 40,273 |
| 15 | single blind$.tw. | 23,241 |
| 16 | double blind$.tw. | 199,780 |
| 17 | ((treble or triple) adj blind$).tw. | 987 |
| 18 | placebo$.tw. | 292,535 |
| 19 | Prospective Study/ | 532,956 |
| 20 | or/1-19 | 2,163,784 |
| 21 | Case Study/ | 62,350 |
| 22 | case report.tw. | 387,117 |
| 23 | abstract report/ or letter/ | 1,111,876 |
| 24 | Conference proceeding.pt. | 0 |
| 25 | Conference abstract.pt. | 3,465,656 |
| 26 | Editorial.pt. | 624,297 |
| 27 | Letter.pt. | 1,075,753 |
| 28 | Note.pt. | 762,274 |
| 29 | or/21-28 | 6,354,079 |
| 30 | 20 not 29 | 1,629,662 |
| 31 | Population terms | exp colorectal cancer/ | 164,843 |
| 32 | (colorectal cancer or colorectal neoplasm or colorectal carcinoma).mp. | 200,650 |
| 33 | 31 or 32 | 201,001 |
| 34 | Intervention terms | exp pembrolizumab/ | 9,946 |
| 35 | (pembrolizumab or MK-3475 or MK3475 or lambrolizumab or keytruda).mp. | 10,545 |
| 36 | (mFOLFOX6 or mFOLFOX-6 or m-FOLFOX6 or m-FOLFOX-6 or modified FOLFOX6 or modified FOLFOX-6).mp. | 1,306 |
| 37 | (FOLFIRI or FOLinic acid-Fluorouracil-IRInotecan).mp. | 3,235 |
| 38 | exp nivolumab/ | 12,029 |
| 39 | (nivolumab or ONO-4538 or BMS-936558 or MDX1106 or opdivo).mp. | 12,605 |
| 40 | exp atezolizumab/ | 3,152 |
| 41 | (atezolizumab or MPDL-3280A or MPDL3280A or RO5541267 or tecentriq).mp. | 3,589 |
| 42 | exp panitumumab/ | 7,590 |
| 43 | (panitumumab or vectibix or ABX-EGF).mp. | 7,912 |
| 44 | exp raltitrexed/ | 2,314 |
| 45 | (raltitrexed disodium or ZD-1694).mp. | 250 |
| 46 | (Folinic Acid or leucovorin or folate).mp. | 69,071 |
| 47 | (Fluorouracil or 5-fluorouracil or 5FU or 5-FU or edufex or fluoroplex or carac or adrucil or tolak).mp. | 139,149 |
| 48 | exp capecitabine/ | 26,957 |
| 49 | (capecitabine or xeloda).mp. | 28,444 |
| 50 | (Irinotecan or camptosar or onivyde).mp. | 36,756 |
| 51 | (Oxaliplatin or eloxatin).mp. | 37,583 |
| 52 | exp cetuximab/ | 26,270 |
| 53 | (cetuximab or erbitux).mp. | 27,100 |
| 54 | (FOLFOX or FOLFOX6 or FOLFOX-6).mp. | 4,740 |
| 55 | exp tegafur/ | 6,468 |
| 56 | (tegafur or ftorafur or Tetrahydrofuranyl-5-Fluorouracil or UFT or UFUR or fluorouracil or "tegafur/uracil" or tegafur-uracil).mp | 144,791 |
| 57 | or/34-56 | 259,285 |
| 58 | Combined | 30 and 33 and 57 | 8,937 |
| 59 | Language | limit 58 to english | 8,259 |

Table S2: Search strategy for MEDLINE

Databases: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) 1946 to July 12, 2019

Search executed on July 15, 2019

|  |  |  |  |
| --- | --- | --- | --- |
| No. | Criteria | Strings | Hits |
| 1 | SIGN filter for clinical trials | Randomized Controlled Trials as Topic/ | 125,042 |
| 2 | randomized controlled trial/ | 485,397 |
| 3 | Random Allocation/ | 99,596 |
| 4 | Double Blind Method/ | 152,159 |
| 5 | Single Blind Method/ | 27,029 |
| 6 | clinical trial/ | 516,915 |
| 7 | clinical trial, phase i.pt | 19,114 |
| 8 | clinical trial, phase ii.pt | 30,820 |
| 9 | clinical trial, phase iii.pt | 15,229 |
| 10 | clinical trial, phase iv.pt | 1,727 |
| 11 | controlled clinical trial.pt | 93,156 |
| 12 | randomized controlled trial.pt | 485,397 |
| 13 | multicenter study.pt | 253,038 |
| 14 | clinical trial.pt | 516,915 |
| 15 | exp Clinical Trials as topic/ | 327,892 |
| 16 | or/1-15 | 1,302,384 |
| 17 | (clinical adj trial$).tw | 337,005 |
| 18 | ((singl$ or doubl$ or treb$ or tripl$) adj (blind$3 or mask$3)).tw | 164,872 |
| 19 | PLACEBOS/ | 34,402 |
| 20 | placebo$.tw | 205,672 |
| 21 | randomly allocated.tw | 26,546 |
| 22 | (allocated adj2 random$).tw | 29,718 |
| 23 | or/17-22 | 594,981 |
| 24 | 16 or 23 | 1,547,712 |
| 25 | case report.tw | 290,868 |
| 26 | letter/ | 1,034,075 |
| 27 | historical article/ | 352,747 |
| 28 | or/25-27 | 1,662,674 |
| 29 | 24 not 28 | 1,512,663 |
| 30 | Population terms | exp colorectal cancer/ | 190,766 |
| 31 | (colorectal cancer or colorectal neoplasm or colorectal carcinoma).mp. | 100,768 |
| 32 | 30 or 31 | 217,120 |
| 33 | Intervention terms | (pembrolizumab or MK-3475 or MK3475 or lambrolizumab or keytruda).mp. | 2,706 |
| 34 | (mFOLFOX6 or mFOLFOX-6 or m-FOLFOX6 or m-FOLFOX-6 or modified FOLFOX6 or modified FOLFOX-6).mp. | 701 |
| 35 | (FOLFIRI or FOLinic acid-Fluorouracil-IRInotecan).mp. | 1,330 |
| 36 | (nivolumab or ONO-4538 or BMS-936558 or MDX1106 or opdivo).mp. | 3,659 |
| 37 | (atezolizumab or MPDL-3280A or MPDL3280A or RO5541267 or tecentriq).mp. | 723 |
| 38 | (panitumumab or vectibix or ABX-EGF).mp. | 1,682 |
| 39 | (raltitrexed disodium or ZD-1694).mp. | 8 |
| 40 | (Folinic Acid or leucovorin or folate).mp. | 37,342 |
| 41 | (Fluorouracil or 5-fluorouracil or 5FU or 5-FU or edufex or fluoroplex or carac or adrucil or tolak).mp. | 54,911 |
| 42 | (capecitabine or xeloda).mp. | 6,519 |
| 43 | (Irinotecan or camptosar or onivyde).mp. | 10,375 |
| 44 | (Oxaliplatin or eloxatin).mp. | 10,676 |
| 45 | exp cetuximab/ | 4,127 |
| 46 | (cetuximab or erbitux).mp. | 6,848 |
| 47 | (FOLFOX or FOLFOX6 or FOLFOX-6).mp. | 2,759 |
| 48 | exp tegafur/ | 5,540 |
| 49 | (tegafur or ftorafur or Tetrahydrofuranyl-5-Fluorouracil or UFT or UFUR or fluorouracil or "tegafur/uracil" or tegafur-uracil).mp | 56,471 |
| 50 | or/33-48 | 108,558 |
| 51 | Combined | 29 and 32 and 50 | 6,814 |
| 52 | Language | limit 51 to english | 6,162 |

Table S3: Search strategy for CENTRAL

Database(s): EBM Reviews - Cochrane Central Register of Controlled Trials October 2019

Search executed on July 15, 2019

|  |  |  |  |
| --- | --- | --- | --- |
| No. | Criteria | Strings | Hits |
| 1 | Population terms | exp colorectal cancer/ | 7,110 |
| 2 | colorectal cancer.mp. | 11,888 |
| 3 | 1 or 2 | 15,167 |
| 4 | Intervention terms | (pembrolizumab or MK-3475 or MK3475 or lambrolizumab or keytruda).mp. | 1,042 |
| 5 | (mFOLFOX6 or mFOLFOX-6 or m-FOLFOX6 or m-FOLFOX-6 or modified FOLFOX6 or modified FOLFOX-6).mp. | 490 |
| 6 | (FOLFIRI or FOLinic acid-Fluorouracil-IRInotecan).mp. | 943 |
| 7 | (nivolumab or ONO-4538 or BMS-936558 or MDX1106 or opdivo).mp. | 1,322 |
| 8 | (atezolizumab or MPDL-3280A or MPDL3280A or RO5541267 or tecentriq).mp. | 490 |
| 9 | (panitumumab or vectibix or ABX-EGF).mp. | 642 |
| 10 | (raltitrexed disodium or ZD-1694).mp. | 1 |
| 11 | (Folinic Acid or leucovorin or folate).mp. | 5,854 |
| 12 | (Fluorouracil or 5-fluorouracil or 5FU or 5-FU or edufex or fluoroplex or carac or adrucil or tolak).mp. | 11,702 |
| 13 | (capecitabine or xeloda).mp. | 3,510 |
| 14 | (Irinotecan or camptosar or onivyde).mp. | 2,995 |
| 15 | (Oxaliplatin or eloxatin).mp. | 4,015 |
| 16 | (FOLFOX or FOLFOX6 or FOLFOX-6).mp. | 1,106 |
| 17 | (cetuximab or erbitux).mp. | 2,107 |
| 18 | exp tegafur/ | 549 |
| 19 | (tegafur or ftorafur or Tetrahydrofuranyl-5-Fluorouracil or UFT or UFUR or fluorouracil or "tegafur/uracil" or tegafur-uracil).mp | 10,939 |
| 20 | or/4-19 | 23,701 |
| 21 | Combined | 3 and 20 | 5,482 |
| 22 | Language | limit 21 to english | 3,275 |

Table S4: Search strategy for Embase - Update

Database: Embase 1974 to April 27, 2020

Search executed: April 28, 2020

|  |  |  |  |
| --- | --- | --- | --- |
| No. | Criteria | Strings | Hits |
| 1 | Population terms | exp colorectal cancer/ | 177,266 |
| 2 | (colorectal cancer or colorectal neoplasm or colorectal carcinoma).mp. | 215,560 |
| 3 | or/1-2 | 215,930 |
| 4 | Intervention terms | exp pembrolizumab/ | 14,209 |
| 5 | (pembrolizumab or MK-3475 or MK3475 or lambrolizumab or keytruda).mp. | 15,010 |
| 6 | exp Nivolumab/ | 16,512 |
| 7 | (nivolumab or ONO-4538 or ONO 4538 or BMS-936558 or BMS 936558 or MDX-1106 or MDX 1106 or MDX1106 or opdivo).mp. | 17,366 |
| 8 | exp atezolizumab/ | 4,681 |
| 9 | (atezolizumab or MPDL-3280A or MPDL3280A or RO5541267 or tecentriq).mp. | 5,202 |
| 10 | exp panitumumab/ | 8,005 |
| 11 | (panitumumab or vectibix or ABX-EGF).mp. | 8,358 |
| 12 | (mFOLFOX6 or mFOLFOX-6 or m-FOLFOX6 or m-FOLFOX-6 or modified FOLFOX6 or modified FOLFOX-6).mp. | 1,458 |
| 13 | (FOLFOX\* or FOLFOX6 or FOLFOX-6 or "folfox regimen").mp. | 6,242 |
| 14 | (FOLFIRI or FOLinic acid-Fluorouracil-IRInotecan).mp. | 3,604 |
| 15 | exp ipilimumab/ | 13,436 |
| 16 | ("Anti-CTLA-4 MAb" or "Anti CTLA 4 MAb Ipilimumab" or "Ipilimumab, Anti-CTLA-4 Mab" or Yervoy or "MDX 010" or "MDX010" or "MDX-010" or "MDX-CTLA-4" or "MDX CTLA 4").mp. | 1,284 |
| 17 | exp bevacizumab/ | 57,246 |
| 18 | (Bevacizumab or Mvasi or "Bevacizumab-awwb" or "Bevacizumab awwb" or Avastin).mp. | 58,930 |
| 19 | exp raltitrexed/ | 2,352 |
| 20 | (raltitrexed disodium or ICI D1694 or ICI-D1694 or ZD-1694 or ZD 1694 or D 1694 or D-1694 or Tomudex).mp. | 808 |
| 21 | exp Leucovorin/ | 36,321 |
| 22 | (Folinic Acid\* or leucovorin\* or folate).mp. | 72,022 |
| 23 | exp fluorouracil/ | 136,981 |
| 24 | (Fluorouracil or 5-fluorouracil or 5FU or 5-FU or edufex or fluoroplex or carac or adrucil or tolak).mp. | 144,121 |
| 25 | exp capecitabine/ | 28,688 |
| 26 | (capecitabine or Xeloda).mp. | 30,404 |
| 27 | exp irinotecan/ | 37,389 |
| 28 | (Irinotecan or CPT-11 or camptosar or onivyde).mp. | 39,134 |
| 29 | exp oxaliplatin/ | 38,806 |
| 30 | (Oxaliplatin or eloxatin).mp. | 40,765 |
| 31 | exp cetuximab/ | 27,750 |
| 32 | (cetuximab or erbitux).mp. | 28,663 |
| 33 | exp tegafur/ | 6,596 |
| 34 | (tegafur or ftorafur or Tetrahydrofuranyl-5-Fluorouracil or UFT or UFUR or fluorouracil or "tegafur/uracil" or tegafur-uracil).mp | 149,945 |
| 35 | or/4-34 | 316,648 |
| 36 | SIGN filter for clinical trials | Clinical Trial/ | 974,317 |
| 37 | Randomized Controlled Trial/ | 601,675 |
| 38 | controlled clinical trial/ | 464,105 |
| 39 | multicenter study/ | 249,739 |
| 40 | Phase 3 clinical trial/ | 46,875 |
| 41 | Phase 4 clinical trial/ | 3,857 |
| 42 | exp RANDOMIZATION/ | 87,020 |
| 43 | Single Blind Procedure/ | 38,786 |
| 44 | Double Blind Procedure/ | 171,947 |
| 45 | Crossover Procedure/ | 62,964 |
| 46 | PLACEBO/ | 349,595 |
| 47 | randomi?ed controlled trial$.tw. | 226,621 |
| 48 | rct.tw. | 36,742 |
| 49 | (random$ adj2 allocat$).tw. | 42,720 |
| 50 | single blind$.tw. | 24,788 |
| 51 | double blind$.tw. | 208,529 |
| 52 | ((treble or triple) adj blind$).tw. | 1,160 |
| 53 | placebo$.tw. | 306,739 |
| 54 | Prospective Study/ | 596,686 |
| 55 | or/36-54 | 2,305,684 |
| 56 | Case Study/ | 68,503 |
| 57 | case report.tw. | 410,313 |
| 58 | abstract report/ or letter/ | 1,141,887 |
| 59 | Conference proceeding.pt. | - |
| 60 | Conference abstract.pt. | 3,764,535 |
| 61 | Editorial.pt. | 650,996 |
| 62 | Letter.pt. | 1,112,321 |
| 63 | Note.pt. | 794,343 |
| 64 | or/56-63 | 6,766,492 |
| 65 | 55 not 64 | 1,713,849 |
| 66 | Combined | 3 AND 35 AND 65 | 9,773 |
| 67 | Language | Limit 66 to English Language | 9,067 |
| 67 | Time | limit 67 to dc=20190715-20200428 | 423 |

Table S5: Search strategy for MEDLINE

Databases: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) 1946 to April 27, 2020

Search executed: April 28, 2020

|  |  |  |  |
| --- | --- | --- | --- |
| No. | Criteria | Strings | Hits |
| 1 | Population terms | exp colorectal cancer/ | 198,609 |
| 2 | (colorectal cancer or colorectal neoplasm or colorectal carcinoma).mp. | 108,136 |
| 3 | or/1-2 | 227,879 |
| 4 | Intervention terms | (pembrolizumab or MK-3475 or MK3475 or lambrolizumab or keytruda).mp. | 3,748 |
| 5 | exp Nivolumab/ | 2,218 |
| 6 | (nivolumab or ONO-4538 or ONO 4538 or BMS-936558 or BMS 936558 or MDX-1106 or MDX 1106 or MDX1106 or opdivo).mp. | 4,755 |
| 7 | (atezolizumab or MPDL-3280A or MPDL3280A or RO5541267 or tecentriq).mp. | 996 |
| 8 | exp panitumumab/ | 956 |
| 9 | (panitumumab or vectibix or ABX-EGF).mp. | 1,793 |
| 10 | (mFOLFOX6 or mFOLFOX-6 or m-FOLFOX6 or m-FOLFOX-6 or modified FOLFOX6 or modified FOLFOX-6).mp. | 742 |
| 11 | (FOLFOX\* or FOLFOX6 or FOLFOX-6 or "folfox regimen").mp. | 3,289 |
| 12 | (FOLFIRI or FOLinic acid-Fluorouracil-IRInotecan).mp. | 1,429 |
| 13 | exp ipilimumab/ | 1,786 |
| 14 | ("Anti-CTLA-4 MAb" or "Anti CTLA 4 MAb Ipilimumab" or "Ipilimumab, Anti-CTLA-4 Mab" or Yervoy or "MDX 010" or "MDX010" or "MDX-010" or "MDX-CTLA-4" or "MDX CTLA 4").mp. | 191 |
| 15 | exp bevacizumab/ | 11,369 |
| 16 | (Bevacizumab or Mvasi or "Bevacizumab-awwb" or "Bevacizumab awwb" or Avastin).mp. | 17,984 |
| 17 | (raltitrexed disodium or ICI D1694 or ICI-D1694 or ZD-1694 or ZD 1694 or D 1694 or D-1694 or Tomudex).mp. | 246 |
| 18 | exp Leucovorin/ | 9,939 |
| 19 | (Folinic Acid\* or leucovorin\* or folate).mp. | 38,779 |
| 20 | exp fluorouracil/ | 46,264 |
| 21 | (Fluorouracil or 5-fluorouracil or 5FU or 5-FU or edufex or fluoroplex or carac or adrucil or tolak).mp. | 56,561 |
| 22 | exp capecitabine/ | 4,222 |
| 23 | (capecitabine or Xeloda).mp. | 6,934 |
| 24 | exp irinotecan/ | 6,906 |
| 25 | (Irinotecan or CPT-11 or camptosar or onivyde).mp. | 11,245 |
| 26 | exp oxaliplatin/ | 6,290 |
| 27 | (Oxaliplatin or eloxatin).mp. | 11,595 |
| 28 | exp cetuximab/ | 4,392 |
| 29 | (cetuximab or erbitux).mp. | 7,275 |
| 30 | exp tegafur/ | 5,686 |
| 31 | (tegafur or ftorafur or Tetrahydrofuranyl-5-Fluorouracil or UFT or UFUR or fluorouracil or "tegafur/uracil" or tegafur-uracil).mp | 58,139 |
| 32 | or/4-31 | 131,720 |
| 33 | SIGN filter for clinical trials | Randomized Controlled Trials as Topic/ | 132,273 |
| 34 | randomized controlled trial/ | 504,474 |
| 35 | Random Allocation/ | 102,598 |
| 36 | Double Blind Method/ | 157,262 |
| 37 | Single Blind Method/ | 28,409 |
| 38 | clinical trial/ | 522,356 |
| 39 | clinical trial, phase i.pt | 20,201 |
| 40 | clinical trial, phase ii.pt | 32,449 |
| 41 | clinical trial, phase iii.pt | 16,500 |
| 42 | clinical trial, phase iv.pt | 1,866 |
| 43 | controlled clinical trial.pt | 93,636 |
| 44 | randomized controlled trial.pt | 504,474 |
| 45 | multicenter study.pt | 270,384 |
| 46 | clinical trial.pt | 522,356 |
| 47 | exp Clinical Trials as topic/ | 339,355 |
| 48 | or/33-47 | 1,355,450 |
| 49 | (clinical adj trial$).tw | 360,848 |
| 50 | ((singl$ or doubl$ or treb$ or tripl$) adj (blind$3 or mask$3)).tw | 171,151 |
| 51 | PLACEBOS/ | 34,831 |
| 52 | placebo$.tw | 213,827 |
| 53 | randomly allocated.tw | 28,236 |
| 54 | (allocated adj2 random$).tw | 31,518 |
| 55 | or/49-54 | 627,776 |
| 56 | 48 or 55 | 1,618,340 |
| 57 | case report.tw | 306,811 |
| 58 | letter/ | 1,072,443 |
| 59 | historical article/ | 357,756 |
| 60 | or/57-59 | 1,721,316 |
| 61 | 56 NOT 60 | 1,581,754 |
| 62 | Combined | 3 AND 32 AND 61 | 7,406 |
| 63 | Language | Limit 62 to English Language | 6,737 |
| 64 | Time | limit 63 to dt=20190715-20200428 | 120 |

Table S6: Search strategy for CENTRAL

Database(s): EBM Reviews - Cochrane Central Register of Controlled Trials March 2020

Search executed on April 28, 2020

|  |  |  |  |
| --- | --- | --- | --- |
| No. | Criteria | Strings | Hits |
| 1 | Population terms | exp colorectal cancer/ | 7,955 |
| 2 | (colorectal cancer or colorectal neoplasm or colorectal carcinoma).mp. | 13,827 |
| 3 | or/1-2 | 17,254 |
| 4 | Intervention terms | (pembrolizumab or MK-3475 or MK3475 or lambrolizumab or keytruda).mp. | 1,425 |
| 5 | (nivolumab or ONO-4538 or ONO 4538 or BMS-936558 or BMS 936558 or MDX-1106 or MDX 1106 or MDX1106 or opdivo).mp. | 1,690 |
| 6 | (atezolizumab or MPDL-3280A or MPDL3280A or RO5541267 or tecentriq).mp. | 684 |
| 7 | (panitumumab or vectibix or ABX-EGF).mp. | 711 |
| 8 | (mFOLFOX6 or mFOLFOX-6 or m-FOLFOX6 or m-FOLFOX-6 or modified FOLFOX6 or modified FOLFOX-6 ).mp. | 582 |
| 9 | (FOLFOX\* or FOLFOX6 or FOLFOX-6 or "folfox regimen").mp. | 1,679 |
| 10 | (FOLFIRI or FOLinic acid-Fluorouracil-IRInotecan).mp. | 1,068 |
| 11 | ("Anti-CTLA-4 MAb" or "Anti CTLA 4 MAb Ipilimumab" or "Ipilimumab, Anti-CTLA-4 Mab" or Yervoy or "MDX 010" or "MDX010" or "MDX-010" or "MDX-CTLA-4" or "MDX CTLA 4").mp. | 121 |
| 12 | (Bevacizumab or Mvasi or "Bevacizumab-awwb" or "Bevacizumab awwb" or Avastin).mp. | 6,386 |
| 13 | (raltitrexed disodium or ICI D1694 or ICI-D1694 or ZD-1694 or ZD 1694 or D 1694 or D-1694 or Tomudex).mp. | 56 |
| 14 | (Folinic Acid\* or leucovorin\* or folate).mp. | 6,342 |
| 15 | (Fluorouracil or 5-fluorouracil or 5FU or 5-FU or edufex or fluoroplex or carac or adrucil or tolak).mp. | 12,415 |
| 16 | (capecitabine or Xeloda).mp. | 3,936 |
| 17 | (Irinotecan or CPT-11 or camptosar or onivyde).mp. | 3,447 |
| 18 | (Oxaliplatin or eloxatin).mp. | 4,539 |
| 19 | (cetuximab or erbitux).mp. | 2,342 |
| 20 | exp tegafur/ | 580 |
| 21 | (tegafur or ftorafur or Tetrahydrofuranyl-5-Fluorouracil or UFT or UFUR or fluorouracil or "tegafur/uracil" or tegafur-uracil).mp | 11,548 |
| 22 | or/4-21 | 30,562 |
| 23 | Combined | 3 AND 22 | 6,462 |
| 24 | Language | limit 23 to english | 3,726 |
| 25 | Time | limit 24 to up=201907-202004 | 1,011 |

Table S7: Eligibility criteria from trials included in systematic review

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Trial ID** | **NCT code** | **Age** | **Study population** | **Performance score** | **Life expectancy** | **Prior chemotherapy** |
| **Included in network meta-analysis** | | | | | | |
| **Falcone et al., 2007** | NCT01219920 | 18 - 75 years | mCRC | ECOG 0-2 | -- | No previous palliative chemotherapy for metastatic disease; No previous chemotherapy including irinotecan or oxaliplatin |
| **GOIM 2802** | 2010-022091-31 | ≥ 18 years | mCRC | ECOG 0-1 | -- | No previous first line chemotherapy treatment; No more than one line of treatment |
| **KEYNOTE 177** | NCT02563002 | ≥ 18 years | dMMR or MSI-H stage IV CRC (100% MSI-h mCRC patients) | ECOG 0-1 | ≥ 3 months | No prior chemotherapy |
| **METHEP** | NCT00208260 | 18 - 75 years | mCRC | WHO 0-1 | ≥ 3 months | No previous adjuvant chemotherapy with irinotecan or oxaliplatin or any treatment for liver metastasis |
| **OLIVIA** | NCT00778102 | ≥ 18 years | mCRC | ECOG 0-1 | -- | No prior systemic or local treatment of metastatic disease; No prior (neo)adjuvant chemotherapy/radiotherapy completed within 6 months prior to study entry |
| **PEAK** | NCT00819780 | ≥ 18 years | mCRC KRAS WT | ECOG 0-1 | -- | No prior chemotherapy or other systemic anticancer therapy for treatment of metastatic colorectal carcinoma |
| **Porschen et al., 2007** | -- | ≥ 18 years | mCRC with MSI-H subgroup | ECOG 0-2 | > 3 months | No prior treatment for mCRC |
| **PRIME** | NCT00364013 | ≥ 18 years | mCRC/mCRC KRAS WT | ECOG 0-2 | -- | No prior chemotherapy or systemic therapy for the treatment of metastatic colorectal carcinoma except: adjuvant fluoropyrimidine-based chemotherapy or prior fluoropyrimidine therapy administered solely for the purpose of radiosensitization |
| **Souglakos et al., 2006** | -- | ≥ 18 years | mCRC | ECOG 0-2 | ≥ 3 months | No previous chemotherapy for metastatic disease |
| **TREE-1** | NCT00399750 | ≥ 18 years | mCRC | ECOG 0-1 | -- | No prior treatment with oxaliplatin or bevacizumab |
| **TREE-2** | NCT00399750 | ≥ 18 years | mCRC | ECOG 0-1 | -- | No prior treatment with oxaliplatin or bevacizumab |
| **TRIBE** | NCT00719797 | 18 - 75 years | mCRC | ECOG 0-2 (≤ 70 years) or ECOG 0 (71-75 years) | ≥ 12 weeks | No prior concurrent therapy: More than 4 weeks since prior radiotherapy; More than 10 days since prior and no concurrent ongoing treatment with anticoagulants for therapeutic purposes; More than 28 days since prior and no concurrent major surgical procedure; More than 28 days since prior open biopsy; More than 30 days since prior investigational agents; No concurrent chronic daily high-dose acetylsalicylic acid (> 325 mg/day) |
| **VISNU-1** | 2012-000846-37 | 18 - 70 years | mCRC | ECOG 0-1 | ≥ 3 months | No previous chemotherapy for metastatic disease; No prior treatment with Bevacizumab, or epidermal growth factor receptor inhibitor |
| **Excluded from network meta-analysis** | | | | | | |
| **2012-03** | NCT01564810 | 18 - 75 years | mCRC KRAS WT | ECOG 0-1 | ≥ 3 months | No previous exposure to target therapy, chemotherapy, radiotherapy or intervention therapy for colorectal liver metastases allowed prior to study entry |
| **ARTIST** | NCT00642577 | ≥ 18 years | mCRC | ECOG 0-1 | > 3 months | No prior systemic therapy for advanced or metastatic disease; No adjuvant or neo-adjuvant treatment for non-metastatic disease in past 6 months. |
| **ATOM** | NCT01836653 | 20 - 80 years | mCRC KRAS WT | ECOG 0-1 | ≥ 3 months | -- |
| **AVF2107** | NCT00109070 | ≥ 18 years | mCRC | ECOG 0-1 | > 3 months | No prior chemotherapy other than adjuvant fluoropyrimidines in combination with leucovorin and/or levamisole.; No administration of adjuvant fluoropyrimidines in combination with leucovorin and/or levamisole completed ≤ 12 months prior to Day 0; No administration of fluoropyrimidines as a radiosensitizer during pelvic radiotherapy for rectal cancer completed ≤ 12 months prior to Day 0; No prior radiotherapy to a measurable, metastatic lesion(s) to be used to measure response; No radiation therapy within 14 days prior to Day 0; No prior biotherapy for colorectal cancer |
| **CALGB 80405** | NCT00265850 | ≥ 18 years | mCRC with MSI-H subgroup | ECOG 0-1 | -- | No prior chemotherapy |
| **CHARTA** | NCT01321957 | ≥ 18 years | mCRC | ECOG 0-2 | > 3 months | -- |
| **CRYSTAL** | NCT00154102 | ≥ 18 years | mCRC KRAS WT | ECOG 0-1 | -- | No prior chemotherapy |
| **FIRE-3** | NCT00433927 | 18 - 75 years | mCRC KRAS WT | ECOG 0-2 | > 3 months | No prior treatment directed against the epidermal growth factor receptor; No prior treatment with bevacizumab; No prior chemotherapy for colorectal cancer, except for adjuvant chemotherapy dating back > 6 months prior to study entry. |
| **GERCOR DREAM** | NCT00265824 | 18 - 80 years | mCRC | ECOG 0-2 | -- | No previous therapy for metastatic disease |
| **ITACa** | NCT01878422 | 18 - 70 years | mCRC | ECOG 0-2 | ≥ 12 weeks | No prior treatment with cetuximab, bevacizumab or other anti-epidermal growth factor receptor or anti-angiogenesis agents; No prior chemotherapy or immunotherapy for metastatic or advanced disease. |
| **Kato et al., 2018** | -- | ≥ 20 years | mCRC | ECOG 0-1 | -- | No prior use of any chemotherapy, immunotherapy or radiation therapy |
| **Madajewicz et al., 2012** | -- | -- | mCRC | ECOG 0-2 | -- | No prior adjuvant chemotherapy or chemoradiation unless completed >6 months before entering this study. |
| **NO16966** | NCT00069095 | ≥ 18 years | mCRC | ECOG 0-1 | -- | No previous treatment with oxaliplatin or bevacizumab; No previous systemic chemotherapy or immunotherapy for advanced or metastatic disease; No progressive disease during or within 6 months of completion of previous adjuvant therapy. |
| **NORDIC VII** | NCT00145314 | 18 - 75 years | mCRC | ECOG 0-2 | > 3 months | No prior chemotherapy for advanced/metastatic disease; No FU-based adjuvant chemotherapy the last 6 months before inclusion; No previous oxaliplatin; |
| **OPUS** | NCT00125034 | ≥ 18 years | mCRC | ECOG 0-2 | ≥ 12 weeks | No previous chemotherapy for colorectal cancer except adjuvant treatment with progression of disease documented > 6 months after end of adjuvant treatment; No previous exposure to epidermal growth factor receptor-targeted or chemotherapy (except adjuvant treatment) for mCRC |
| **Personeni et al., 2013** | NCT01068132 | 18 - 80 years | mCRC KRAS WT | ECOG 0-1 | -- | No previous chemotherapy for metastatic CRC (any). Adjuvant therapy is allowed if the chemotherapy treatment free interval is > 6 months; No surgery (excluding diagnostic biopsy) or irradiation within 4 weeks prior to study entry; No concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy not indicated in the study protocol; No investigational agent(s) within 4 weeks prior to entry; No previous exposure to HER-axis -pathway targeting therapy |
| **Stathopoulos et al., 2010** | -- | ≥ 18 years | mCRC | WHO 0 - 2 | ≥ 12 weeks | -- |
| **TAILOR** | NCT01228734 | ≥ 18 years | mCRC KRAS WT | ECOG 0-1 | ≥ 12 weeks | No previous chemotherapy for CRC except adjuvant treatment if terminated > 9 months (oxaliplatin-based chemotherapy) or > 6 months (non-oxaliplatin-based chemotherapy) before the start of treatment in this trial; No radiotherapy or surgery (excluding prior diagnostic biopsy) in the 30 days before trial treatment; No previous treatment with monoclonal antibody therapy, vascular endothelial growth factor pathway-targeting therapy, epidermal growth factor receptor pathway-targeting therapy, or other signal transduction inhibitors |

Abbreviations: dMMR, DNA mismatch repair; MSI-H, microstatellite instability high; mCRC, metastatic colorectal cancer; WT, Wild-type.

Table S8: Patient characteristics from trials included in systematic review

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Trial ID** | **Population** | **Treatment** | **Sample**  **size** | **Age,**  **median (range)** | **Male,**  **N (%)** | **ECOG 0,**  **N (%)** | **ECOG 1,**  **N (%)** | **ECOG 2,**  **N (%)** | **Rectum site,**  **N (%)** | **Colon site, N (%)** |
| **Included in network meta-analysis** | | | | | | | | | | |
| **Falcone et al., 2007** | mCRC | FOLFIRI | 122 | 64 (21-75) | 69 (56.6) | 74 (60.7) | 41 (33.6) | 7 (5.7) | 27 (22) | 95 (78) |
| FOLFOXIRI | 122 | 62 (27-75) | 75 (61.5) | 74 (60.7) | 45 (36.9) | 3 (2.5) | 41 (34) | 81 (66) |
| **GOIM 2802** | mCRC | FOLFOX4 + bevacizumab | 45 | 62 (42-73) | 22 (48.9) | 14 (31.1) | 31 (68.9) | -- | 7 (15.6) | 35 (77.8) |
| XELOX2 + bevacizumab | 87 | 66 (32-77) | 46 (52.9) | 34 (39.1) | 53 (60.9) | -- | 18 (20.9) | 64 (74.4) |
| **KEYNOTE 177** | MSI-H mCRC | Pembrolizumab | 153 | 63 (24-93) | 71 (46.4) | 75 (49) | -- | -- | -- | 148 (96.7) |
| SOC | 154 | 62.5 (26-90) | 82 (53.2) | 84 (54.5) | -- | -- | -- | 149 (96.8) |
| **METHEP** | mCRC | FOLFIRI/FOLFOX4 | 30 | 62.5 (47-73) | 15 (50) | 21 (70) | 8 (26.7) | -- | 3 (10) | 27 (90) |
| FOLFIRI-HD | 32 | 62.5 (46-73) | 12 (37.5) | 24 (75) | 7 (21.9) | -- | 6 (19) | 26 (81.2) |
| FOLFOX7 | 30 | 59 (39-80) | 24 (80) | 21 (70) | 9 (30) | -- | 5 (17) | 25 (83.3) |
| FOLFOXIRI | 30 | 64 (43-74) | 18 (60) | 23 (76.7) | 7 (23.3) | -- | 4 (13) | 18 (60) |
| **OLIVIA** | mCRC | FOLFOXIRI + bevacizumab | 41 | 63 (32-77) | 29 (70.7) | 23 (56.1) | 16 (39) | 2 (4.9) | 8 (20) | 29 (71) |
| mFOLFOX6 + bevacizumab | 39 | 57 (28-80) | 18 (46.2) | 31 (79.5) | 8 (20.5) | 0 (0) | 9 (23) | 27 (69) |
| **PEAK** | mCRC KRAS WT | mFOLFOX6 + panitumumab | 142 | 63 (23-82) | 86 (60.6) | 89 (62.7) | 53 (37.3) | -- | 46 (32) | 96 (68) |
| mFOLFOX6 + bevacizumab | 143 | 61 (28-82) | 96 (67.1) | 91 (63.6) | 51 (35.7) | -- | 51 (36) | 92 (64) |
| **Porschen et al., 2007** | mCRC | FOLFOX | 233 | 64 (34-86) | 146 (62.7) | -- | -- | 17 (7.3) | -- | -- |
| XELOX | 241 | 66 (32-81) | 150 (62.2) | -- | -- | 22 (9.1) | -- | -- |
| **PRIME** | mCRC KRAS WT | FOLFOX4 + panitumumab | 325 | 62 (27-85) | 217 (66.8) | -- | -- | -- | 111 (34) | 214 (66) |
| FOLFOX4 | 331 | 61 (24-82) | 204 (61.6) | -- | -- | -- | 115 (35) | 216 (65) |
| **Souglakos et al., 2006** | mCRC | FOLFIRI | 146 | 66 (39-84) | 82 (56.2) | 55 (37.7) | 74 (50.7) | 17 (11.6) | 36 (25) | 110 (75) |
| FOLFOXIRI | 137 | 66 (25-82) | 76 (55.5) | 49 (35.8) | 73 (53.3) | 15 (10.9) | 37 (27) | 100 (73) |
| **TREE-1** | mCRC | mFOLFOX6 | 49 | 62 (35-79) | 28 (57) | 30 (61) | 19 (31) | -- | -- | -- |
| bFOLFOX | 50 | 62 (31-84) | 31 (62) | 29 (58) | 21 (42) | -- | -- | -- |
| XELOX | 48 | 62.5 (32-84) | 31 (65) | 25 (52) | 23 (39) | -- | -- | -- |
| **TREE-2** | mCRC | mFOLFOX6 + bevacizumab | 71 | 64 (31-83) | 43 (61) | 43 (61) | 28 (39) | -- | -- | -- |
| bFOLFOX + bevacizumab | 70 | 57 (30-85) | 34 (49) | 38 (54) | 32 (46) | -- | -- | -- |
| XELOX + bevacizumab | 72 | 62 (32-82) | 42 (58) | 47 (65) | 25 (35) | -- | -- | -- |
| **TRIBE** | mCRC | FOLFIRI + bevacizumab | 256 | 60 (29-75) | 156 (60.9) | 229 (89.5) | -- | -- | -- | 240 (93.8) |
| FOLFOXIRI + bevacizumab | 252 | 60.5 (29-75) | 150 (59.5) | 227 (90.1) | -- | -- | -- | 240 (95.2) |
| **VISNU-1** | mCRC | mFOLFOX6 + bevacizumab | 177 | 59 (27-70) | 119 (67.2) | 85 (48) | 92 (52) | -- | -- | 177 (100) |
| FOLFOXIRI + bevacizumab | 172 | 61 (37-70) | 118 (68.6) | 81 (47.1) | 91 (52.9) | -- | -- | 172 (100) |
| **Excluded from network meta-analysis** | | | | | | | | | | |
| **2012-03** | mCRC KRAS WT | mFOLFOX6 or FOLFIRI + cetuximab | 70 | 57 (26-75) | 46 (65.7) | 58 (82.9) | 12 (17.1) | -- | 26 (37.1) | 44 (62.9) |
| mFOLFOX6 or FOLFIRI | 68 | 59 (35-75) | 42 (61.8) | 54 (79.4) | 14 (20.6) | -- | 30 (44.1) | 38 (55.9) |
| **ARTIST** | mCRC | mFOLFIRI + bevacizumab | 139 | 53 (23-77) | 70 (50.4) | 66 (47.5) | 73 (52.5) | -- | 66 (47.5) | 66 (47.5) |
| mFOLFIRI | 64 | 50 (22-72) | 36 (56.2) | 23 (35.9) | 41 (64.1) | -- | 32 (50) | 31 (48.4) |
| **ATOM** | mCRC KRAS WT | mFOLFOX + bevacizumab | 57 | 64 (32-80) | 34 (59.6) | 51 (89.5) | 6 (10.5) | -- | -- | 57 (100) |
| mFOLFOX + cetuximab | 59 | 65 (42-79) | 34 (57.6) | 51 (86.4) | 8 (13.6) | -- | -- | 59 (100) |
| **AVF2107** | mCRC | FOLFIRI + placebo | 411 | 60 (21-83) | 248 (60.3) | 227 (55.2) | 182 (44.3) | 2 (0.5) | 77 (18.7) | 334 (81.3) |
| FOLFIRI + bevacizumab | 402 | 60 (23-86) | 237 (59) | 234 (58.2) | 166 (41.3) | 1 (0.2) | 92 (22.9) | 310 (77.1) |
| **CALGB 80405** | mCRC KRAS WT | FOLFOX or FOLFIRI + bevacizumab | 559 | 59 (21.8-85) | 348 (62.6) | 324 (58) | 233 (41.7) | 2 (0.4) | -- | 476 (85.2) |
| FOLFOX or FOLFIRI + cetuximab | 578 | 59.2 (20.8-89.5) | 349 (60.4) | 333 (57.6) | 245 (42.4) | 0 (0) | -- | 493 (85.3) |
| **CHARTA** | mCRC | FOLFOX + bevacizumab | -- | -- | -- | -- | -- | -- | -- | -- |
| FOLFOXIRI + bevacizumab | -- | -- | -- | -- | -- | -- | -- | -- |
| **CRYSTAL** | mCRC KRAS WT | FOLFIRI + cetuximab | 316 | 61 (24-79) | -- | -- | -- | -- | -- | -- |
| FOLFIRI | 350 | 59 (19-84) | -- | -- | -- | -- | -- | -- |
| **FIRE-3** | mCRC | FOLFIRI + cetuximab | 297 | 64 (38-79) | 214 (72.1) | 154 (51.9) | 136 (45.8) | 7 (2.4) | 115 (39) | 168 (57) |
| FOLFIRI + bevacizumab | 295 | 65 (27-76) | 196 (66.4) | 158 (53.6) | 133 (45.1) | 4 (1.4) | 106 (36) | 177 (60) |
| **GERCOR DREAM** | mCRC | mFOLFOX7 + bevacizumab | 156 | -- | -- | -- | -- | -- | -- | -- |
| XELOX2 + bevacizumab | 154 | -- | -- | -- | -- | -- | -- | -- |
| **ITACa** | mCRC | FOLFOX4 or FOLFIRI + bevacizumab | 176 | 66 (34-83) | 108 (61.4) | 144 (81.8) | -- | -- | 41 (23.3) | 135 (76.7) |
| FOLFOX4 or FOLFIRI | 194 | 66 (33-82) | 115 (59.3) | 154 (79.4) | -- | -- | 51 (26.3) | 143 (73.7) |
| **Kato et al., 2018** | mCRC | mFOLFOX6 + bevacizumab | 49 | 63 (35-81) | 33 (67.3) | 40 (81.6) | 5 (10.2) | -- | 20 (40.8) | 29 (59.2) |
| XELOX + bevacizumab | 19 | 68 (47-77) | 17 (89.5) | 16 (84.2) | 1 (5.3) | -- | 5 (26.3) | 14 (73.7) |
| **Madajewicz et al., 2012** | mCRC | FOLFOX4 | 24 | 64 (32-81) | 9 (37.5) | 13 (54.2) | 11 (45.8) | -- | 4 (16.7) | 18 (75) |
| FOLFOX4 + bevacizumab | 18 | 64 (42-81) | 11 (61.1) | 7 (38.9) | 11 (61.1) | -- | 0 (0) | 17 (94.4) |
| **NO16966** | mCRC | XELOX | 317 | 61 (24-84) | 194 (61.2) | 160 (50.5) | 157 (49.5) | 0 (0) | 83 (26) | 204 (64) |
| FOLFOX4 | 317 | 62 (24-83) | 204 (64.4) | 163 (51.4) | 154 (48.6) | 0 (0) | 100 (32) | 200 (63) |
| XELOX + placebo | 350 | 61 (18-83) | 205 (58.6) | 207 (59.1) | 143 (40.9) | 0 (0) | 87 (25) | 233 (67) |
| FOLFOX4 + placebo | 351 | 60 (26-83) | 189 (53.8) | 211 (60.1) | 138 (39.3) | 0 (0) | 94 (27) | 232 (66) |
| XELOX + bevacizumab | 350 | 61 (18-86) | 213 (60.9) | 207 (59.1) | 142 (40.6) | 1 (0.3) | 82 (23) | 236 (67) |
| FOLFOX4 + bevacizumab | 349 | 60 (19-82) | 205 (58.7) | 198 (56.7) | 147 (42.1) | 0 (0) | 98 (28) | 223 (64) |
| **NORDIC VII** | mCRC KRAS WT | FOLFOX | 97 | 60 (35.2-74.6) | -- | -- | -- | -- | 35 (36) | 62 (64) |
| FOLFOX + cetuximab | 97 | 60 (24.1-74.4) | -- | -- | -- | -- | 42 (43) | 55 (57) |
| **OPUS** | mCRC | FOLFOX4 | 168 | 60 (30-82) | 92 (54.8) | 75 (44.6) | 76 (45.2) | 17 (10.1) | 79 (47) | 89 (53) |
| FOLFOX4 + cetuximab | 169 | 62 (24-82) | 89 (52.7) | 65 (38.5) | 89 (52.7) | 15 (8.9) | 75 (44) | 92 (54) |
| **Personeni et al., 2013** | mCRC KRAS WT | FOLFIRI + cetuximab | 54 | -- | -- | -- | -- | -- | -- | -- |
| FOLFIRI | 35 | -- | -- | -- | -- | -- | -- | -- |
| **Stathopo-ulos et al., 2010** | mCRC | FOLFIRI + bevacizumab | 114 | 67 (45-82) | 73 (64) | -- | -- | 29 (25.4) | -- | -- |
| FOLFIRI | 108 | 62 (30-87) | 68 (63) | -- | -- | 30 (27.8) | -- | -- |
| **TAILOR** | mCRC RAS WT | FOLFOX4 + cetuximab | 193 | 56 (21-83) | 127 (65.8) | 63 (32.6) | 130 (67.4) | -- | 90 (46.6) | 93 (48.2) |
| FOLFOX4 | 200 | 56 (21-78) | 139 (69.5) | 66 (33) | 134 (67) | -- | 93 (46.5) | 105 (52.5) |

Abbreviations: bFOLFOX, bolus fluorouracil + low-dose leucovorin + oxaliplatin; ECOG, Eastern Cooperative Oncology Group; FOLFIRI, 5-fluorouracil + leucovorin + irinotecan; FOLFOX, 5-fluorouracil + leucovorin + oxaliplatin; FOLFOXIRI, 5-fluorouracil + leucovorin + oxaliplatin + irinotecan; HD, High dose; mCRC, metastatic colorectal cancer; MSI-H, microstatellite instability high; SOC, standard of care; WT, wild-type; XELOX, oxaliplatin + Capecitabine.

Table S9: Outcomes from trials included in systematic review

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Trial ID** | **Population** | **Treatment** | **Sample size** | **Median follow-**  **up time** | **ORR, %** | **Median OS,**  **month (95% CI)** | **OS HR**  **(95% CI)** | **Median PFS,**  **month (95% CI)** | **PFS HR**  **(95% CI)** |
| **Included in network meta-analysis** | | | | | | | | | |
| **Falcone et al., 2007** | mCRC | FOLFIRI | 122 | 60.6 months | -- | 16.7 (13.8-19.4) | -- | 6.8 (5.5-7.8) | -- |
| FOLFOXIRI | 122 | 60.6 months | -- | 23.4 (19.8-25.6) | 0.74 (0.56-0.96) | 9.8 (9.4-10.6) | 0.59 (0.45-0.76) |
| **GOIM 2802** | mCRC | FOLFOX4 + bevacizumab | 45 | 47.2 months | 55.6% | 29.8 | -- | 10 | -- |
| XELOX2 + bevacizumab | 87 | 47.2 months | 48.3% | 25 | 1.21 (0.77-1.92) | 9.9 | 0.96 (0.65-1.41) |
| **KEYNOTE 177** | MSI-H mCRC | Pembrolizumab | 153 | -- | 43.8% | NR | 0.77 (0.54-1.09) | 16.5 (5.4-32.4) | 0.6 (0.45-0.8) |
| SOC | 154 | -- | 33.1% | 34.8 (26.3-NR) | -- | 8.2 (6.1-10.2) | -- |
| **METHEP** | mCRC | FOLFIRI/FOLFOX4 | 30 | 50.4 months | 33% | 17.7 (13.7-43) | -- | 9.2 (6.8-13.4) | -- |
| FOLFIRI-HD | 32 | 50.4 months | 47% | 29.4 (26.1-42.4) | -- | 12.1 (10.3-16.6) | -- |
| FOLFOX7 | 30 | 50.4 months | 43% | 26.9 (18.7-45) | -- | 8.5 (6.4-10.9) | -- |
| FOLFOXIRI | 30 | 50.4 months | 57% | 48.8 (21.9-NR) | -- | 14.1 (11.2-21.7) | -- |
| **OLIVIA** | mCRC | FOLFOXIRI + bevacizumab | 39 | -- | 62% | 32.2 | -- | 11.5 (9.6-13.6) | -- |
| mFOLFOX6 + bevacizumab | 41 | -- | 81% | NR | 0.35 (0.15-0.8) | 18.6 (12.9-22.3) | 0.43 (0.26-0.72) |
| **PEAK** | mCRC KRAS WT | mFOLFOX6 + panitumumab | 142 | -- | 57.8% | 34.2 (26.6-NR) | 0.62 (0.44-0.89) | 10.9 (9.4-13) | 0.87 (0.65-1.17) |
| mFOLFOX6 + bevacizumab | 143 | -- | 53.5% | 24.3 (21-29.2) | -- | 10.1 (9-12.6) | -- |
| **Porschen et al., 2007** | mCRC | FOLFOX | 233 | 17.3 months | 54% | 18.8 | -- | 8 | -- |
| XELOX | 241 | 17.3 months | 48% | 16.8 | 1.12 (0.92-1.38) | 7.1 | 1.17 (0.96-1.43) |
| **PRIME** | mCRC KRAS WT | FOLFOX4 + panitumumab | 325 | 89 weeks | 57% | 23.8 (20-27.7) | 0.83 (0.7-0.98) | 10 (9.3-11.4) | 0.8 (0.67-0.95) |
| FOLFOX4 | 331 | 74 weeks | 48% | 19.4 (17.4-22.6) | -- | 8.6 (7.5-9.5) | -- |
| **Souglakos et al., 2006** | mCRC | FOLFIRI | 146 | 26 months | 33.6% | 19.5 | -- | -- | -- |
| FOLFOXIRI | 137 | 26 months | 43% | 21.5 | 0.93 (0.69-1.25) | -- | -- |
| **TREE-1** | mCRC | mFOLFOX6 | 49 | 16.9 months | 41% | 19.2 (14.2-24.9) | -- | -- | -- |
| bFOLFOX | 50 | 15.1 months | 20% | 17.9 (11.5-24.6) | -- | -- | -- |
| XELOX | 48 | 15 months | 27% | 17.2 (12.5-22.3) | -- | -- | -- |
| **TREE-2** | mCRC | mFOLFOX6 + bevacizumab | 71 | 17.9 months | 52% | 26.1 (18-NR) | -- | -- | -- |
| bFOLFOX + bevacizumab | 70 | 17.6 months | 39% | 20.4 (18.4-25.3) | -- | -- | -- |
| XELOX + bevacizumab | 72 | 18.5 months | 46% | 24.6 (21.4-31.6) | -- | -- | -- |
| **TRIBE** | mCRC | FOLFIRI + bevacizumab | 256 | 48.1 months | 54% | 25.8 (22.5-29.1) | -- | 9.7 (9.2-10.9) | -- |
| FOLFOXIRI + bevacizumab | 252 | 48.1 months | 65% | 29.8 (26-34.3) | 0.8 (0.65-0.98) | 12.3 (11-13.3) | 0.77 (0.65-0.93) |
| **VISNU-1** | mCRC | mFOLFOX6 + bevacizumab | 177 | 50.7 months | 52% | 17.6 | -- | 9.3 | -- |
| FOLFOXIRI + bevacizumab | 172 | 50.7 months | 59% | 22.3 | 0.84 (0.66-1.06) | 12.4 | 0.64 (0.49-0.82) |
| **Excluded from network meta-analysis** | | | | | | | | | |
| **2012-03** | mCRC KRAS WT | mFOLFOX6 or FOLFIRI + cetuximab | 70 | 25 months | 57.1% | 30.9 (16.5-41.5) | 0.54 (0.33-0.89) | 10.2 (8.6-11.4) | 0.6 (0.41-0.87) |
| mFOLFOX6 or FOLFIRI | 68 | 25 months | 29.4% | 21 (16.7-23.4) | -- | 5.8 (3.9-6.1) | -- |
| **ARTIST** | mCRC | mFOLFIRI + bevacizumab | 139 | -- | 35.3% | 18.7 (15.8-19.6) | 0.62 (0.41-0.95) | 8.3 (7.4-8.9) | 0.44 (0.31-0.63) |
| mFOLFIRI | 64 | -- | 17.2% | 13.4 (9.7-17.2) | -- | 4.2 (3.7-4.9) | -- |
| **ATOM** | mCRC KRAS WT | mFOLFOX + bevacizumab | 57 | 24.3 months | 68.4% | 30.4 | -- | 11.5 (9.2-13.3) | -- |
| mFOLFOX + cetuximab | 59 | 24.3 months | 84.7% | -- | 0.83 (0.44-1.56) | 14.8 (9.7-13.3) | 0.80 (0.51-1.26) |
| **AVF2107** | mCRC | FOLFIRI + placebo | 411 | -- | 34.8% | 15.6 | 0.66  (0.55-0.82)\* | 6.2 | 0.54  (0.48-0.68) \* |
| FOLFIRI + bevacizumab | 402 | -- | 44.8% | 20.3 | -- | 10.6 | -- |
| **CALGB 80405** | mCRC KRAS WT | FOLFOX or FOLFIRI + bevacizumab | 559 | 47.4 months | 55.2% | 29 | 0.88 (0.77-1.01) | 10.6 (6.4-16.6) | 0.95 (0.84-1.08) |
| FOLFOX or FOLFIRI + cetuximab | 578 | 47.4 months | 59.6% | 30 | -- | 10.5 (5.8-17.7) | -- |
| **CHARTA** | mCRC | FOLFOX + bevacizumab | -- | -- | 60% | 24.9 | -- | 9.76 | -- |
| FOLFOXIRI + bevacizumab | -- | -- | 70% | 27.9 | -- | 12 | 0.77 |
| **CRYSTAL** | mCRC KRAS WT | FOLFIRI | 350 | 46.2 months | 39.7% | 20 (17.4-21.7) | -- | 8.4 (7.4-9.2) | -- |
| FOLFIRI + cetuximab | 316 | 46.8 months | 57.3% | 23.5 (21.2-26.3) | 0.80 (0.67-0.95) | 9.9 (9-11.3) | 0.80 (0.56-0.87) |
| **FIRE-3** | mCRC | FOLFIRI + cetuximab | 297 | 33 months | 62% | 28.7 (24-30.6) | 0.77 (0.62-0.96) | 10 (8.8-10.8) | 1.06 (0.88-1.26) |
| FOLFIRI + bevacizumab | 295 | 39 months | 58% | 25 (22.7-27.6) | -- | 10.3 (9.8-11.3) | -- |
| **GERCOR DREAM** | mCRC | mFOLFOX7 + bevacizumab | 156 | -- | 50% | 26.6 | 1.24 (0.98-1.59) | 7.9 | 0.98 (0.74-1.31) |
| XELOX2 + bevacizumab | 154 | -- | 49.3% | 23.4 | -- | 8.7 | -- |
| **ITACa** | mCRC | FOLFOX4 or FOLFIRI + bevacizumab | 176 | 36 months | 50.6% | 20.8 (15.9-23.2) | 1.13 (0.89-1.43) | 9.6 (8.2-10.3) | 0.86 (0.7-1.07) |
| FOLFOX4 or FOLFIRI | 194 | 36 months | 50% | 21.3 (19.9-24.1) | -- | 8.4 (7.2-9) | -- |
| **Kato et al., 2018** | mCRC | mFOLFOX6 + bevacizumab | 49 | -- | 55.1% | 29 (24.4-40.9) | -- | 11.3 (9.1-15.5) | -- |
| XELOX + bevacizumab | 19 | -- | 42.1% | 22.5 (15.5-34.9) | -- | 8 (4.2-16.8) | -- |
| **Madajewicz et al., 2012** | mCRC | FOLFOX4 | 24 | -- | 33.3% | 10.9 (9.1-21.3) | -- | -- | -- |
| FOLFOX4 + bevacizumab | 18 | -- | 50% | 32 (19.7-NR) | -- | -- | -- |
| **NO16966** | mCRC | XELOX + Placebo/XELOX | 667 | -- | -- | 19 | -- | -- | -- |
| FOLFOX-4 + Placebo/FOLFOX-4 | 668 | -- | -- | 18.9 | -- | -- | -- |
| XELOX + Bevacizumab | 350 | -- | -- | 21.6 | -- | -- | -- |
| FOLFOX4 + Bevacizumab | 349 | -- | -- | 21 | -- | -- | -- |
| **NORDIC VII** | mCRC KRAS WT | FOLFOX | 97 | -- | 47% | 22 (17.9-26.1) | -- | 8.7 (7.4-9.9) | -- |
| FOLFOX + cetuximab | 97 | -- | 46% | 20.1 (14.5-25.7) | 1.14 (0.8-1.61) | 7.9 (6.3-9.5) | 1.07 (0.79-1.45) |
| **OPUS** | mCRC | FOLFOX4 | 168 | -- | 36% | 18 (16.7-21.8) | -- | 7.2 (6-7.8) | -- |
| FOLFOX4 + cetuximab | 169 | -- | 46% | 18.3 (14.8-20.4) | 1.02 (0.79-1.30) | 7.2 (5.6-7.7) | 0.93 (0.71-1.2) |
| **Personeni et al., 2013** | mCRC KRAS WT | FOLFIRI + cetuximab | 54 | -- | 52.3% | 23.3 | -- | 6.8 | -- |
| FOLFIRI | 35 | -- | 52% | 17.7 | -- | 8.2 | -- |
| **Stathopoulos et al., 2010** | mCRC | FOLFIRI + bevacizumab | 114 | 36 months | 36.8% | 22 (18.1-25.9) | 1.26  (0.95-1.66)\* | -- | -- |
| FOLFIRI | 108 | 36 months | 35.2% | 25 (18.1-31.9) | -- | -- | -- |
| **TAILOR** | mCRC RAS WT | FOLFOX4 + cetuximab | 193 | 44.4 months | 61.1% | 20.7 (15.9-22.1) | 0.76 (0.61-0.95) | 9.2 (7.7-9.4) | 0.69 (0.54-0.89) |
| FOLFOX4 | 200 | 48.7 months | 39.5% | 17.8 (14.9-19.6) | -- | 7.4 (5.6-7.9) | -- |

Abbreviations: bFOLFOX, bolus fluorouracil + low-dose leucovorin + oxaliplatin; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; FOLFIRI, 5-fluorouracil + leucovorin + irinotecan; FOLFOX, 5-fluorouracil + leucovorin + oxaliplatin; FOLFOXIRI, 5-fluorouracil + leucovorin + oxaliplatin + irinotecan; HD, High dose; HR, hazard ratio; mCRC, metastatic colorectal cancer; MSI-H, microstatellite instability High; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; SOC, standard of care; WT, wild-type; XELOX, oxaliplatin + capecitabine.

\* Hazard ratios or confidence intervals derived from Kaplan-Meier curves

Table S10: Proportional hazard assumption test (Grambsch and Therneau test) of trials included in the analysis

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Study | Intervention | Comparator | Test for proportional hazard (Overall Survival)\* | Test for proportional hazard (Progression-free Survival)\* |
| **Falcone et al., 2007** | FOLFIXIRI | FOLFIRI | p = 0.221 | p = 0.029 |
| **GOIM 2802** | XELOX2 + Bevacizumab | FOLFOX4 + Bevacizumab | p = 0.262 | p = 0.225 |
| **KEYNOTE-177** | Pembrolizumab | SOC | p = 0.062 (unadjusted for crossover)  p = 0.008 (adjustment for crossover using 2-stage model)  p = 0.018 (adjustment for crossover using RPSFT method) | p < 0.001 |
| **METHEP** | FOLFIXIRI | Pooled FOLFOX or FOLFIRI | p = 0.353 | p = 0.08 |
| **OLIVIA** | FOLFIXIRI + Bevacizumab | mFOLFOX6 + Bevacizumab | -- | p = 0.693 |
| **PEAK** | mFOLFOX6 + Panitumumab | mFOLFOX6 + Bevacizumab | p = 0.397 | p = 0.796 |
| **Porschen et al., 2007** | XELOX | FOLFOX | p = 0.643 | p = 0.213 |
| **PRIME** | FOLFOX4 + Panitumumab | FOLFOX4 | p = 0.712 | p = 0.567 |
| **Souglakos et al., 2006** | FOLFIXIRI | FOLFIRI | p = 0.98 | -- |
| **TREE-1** | XELOX | Pooled FOLFOX | p = 0.003 | -- |
| **TREE-2** | XELOX + Bevacizumab | Pooled FOLFOX + Bevacizumab | p = 0.173 | -- |
| **TRIBE** | FOLFIXIRI + Bevacizumab | FOLFIRI + Bevacizumab | p = 0.455 | p = 0.022 |
| **VISNU-1** | FOLFIXIRI + Bevacizumab | mFOLFOX6 + Bevacizumab | p = 0.519 | p = 0.266 |

Abbreviations: FOLFIRI, 5-fluorouracil + leucovorin + irinotecan; FOLFOX, 5-fluorouracil + leucovorin + oxaliplatin; FOLFOXIRI, 5-fluorouracil + leucovorin + oxaliplatin + irinotecan; HD, High dose; HR, hazard ratio; mCRC, metastatic colorectal cancer; SOC, standard of care; XELOX, oxaliplatin + capecitabine.

\* p < 0.05 considered violation of proportional hazards assumption

Table S11: Estimated constant hazard ratios of overall survival with pembrolizumab versus competing interventions from fixed-effect and random-effects network meta-analysis; no adjustment for crossover in KEYNOTE-177

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Hazard Ratio (95% credible intervals), fixed-effect** | | | | | | |
| **SOC** |  |  |  |  |  |  |
| 1.05  (0.87, 1.25) | **XELOX** |  |  |  |  |  |
| 1.06  (0.81, 1.38) | 1.01  (0.73, 1.39) | **XELOX + Bevacizumab** |  |  |  |  |
| **0.81  (0.67, 0.97)** | 0.77  (0.59, 1.00) | 0.76  (0.55, 1.06) | **FOLFOXIRI** |  |  |  |
| **0.80  (0.68, 0.93)** | **0.76  (0.60, 0.96)** | 0.75  (0.56, 1.02) | 0.98  (0.77, 1.25) | **FOLFOXIRI + Bevacizumab** |  |  |
| **0.79  (0.67, 0.92)** | **0.75  (0.60, 0.95)** | 0.74  (0.55, 1.01) | 0.97  (0.77, 1.24) | 0.99  (0.80, 1.23) | **FOLFOX + Panitumumab** |  |
| 0.77  (0.54, 1.09) | 0.73  (0.49, 1.09) | 0.73  (0.47, 1.13) | 0.95  (0.64, 1.41) | 0.96  (0.66, 1.41) | 0.98  (0.66, 1.43) | **Pembrolizumab** |
| **Hazard Ratio (95% credible intervals),** **random-effects** | | | | | | |
| **SOC** |  |  |  |  |  |  |
| 1.02  (0.72, 1.37) | **XELOX** |  |  |  |  |  |
| 1.07  (0.75, 1.54) | 1.05  (0.67, 1.74) | **XELOX + Bevacizumab** |  |  |  |  |
| 0.81  (0.61, 1.05) | 0.79  (0.53, 1.24) | 0.76  (0.48, 1.17) | **FOLFOXIRI** |  |  |  |
| **0.77  (0.55, 0.98)** | 0.76  (0.49, 1.13) | 0.72  (0.43, 1.10) | 0.96  (0.62, 1.37) | **FOLFOXIRI + Bevacizumab** |  |  |
| 0.76  (0.54, 1.00) | 0.75  (0.48, 1.16) | 0.72  (0.43, 1.11) | 0.95  (0.61, 1.37) | 0.99  (0.66, 1.53) | **FOLFOX + Panitumumab** |  |
| 0.77  (0.47, 1.26) | 0.76  (0.43, 1.40) | 0.72  (0.39, 1.32) | 0.96  (0.54, 1.69) | 1.00  (0.58, 1.83) | 1.01  (0.58, 1.86) | **Pembrolizumab** |

**Abbreviations**: FOLFOX, 5-fluorouracil + leucovorin + oxaliplatin; FOLFOXIRI, 5-fluorouracil + leucovorin + oxaliplatin + irinotecan; SOC, standard of care; XELOX, oxaliplatin + capecitabine.

**Notes**: Each cell represents the comparison (hazard ratio and 95% credible intervals) of the row treatment versus the column treatment; All bolded values are statistically meaningful at the 0.05 significance level.

Table S12: Estimated constant hazard ratios of overall survival with pembrolizumab versus competing interventions from fixed-effect and random-effects network meta-analysis; adjustment for crossover in KEYNOTE-177 using 2-stage model

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Hazard Ratio (95% credible intervals), fixed-effect** | | | | | | |
| **SOC** |  |  |  |  |  |  |
| 1.05  (0.88, 1.25) | **XELOX** |  |  |  |  |  |
| 1.06  (0.81, 1.38) | 1.01  (0.73, 1.39) | **XELOX + Bevacizumab** |  |  |  |  |
| **0.81  (0.67, 0.97)** | **0.78  (0.60, 0.99)** | 0.76  (0.56, 1.05) | **FOLFOXIRI** |  |  |  |
| **0.79  (0.68, 0.92)** | **0.76  (0.60, 0.96)** | 0.75  (0.55, 1.01) | 0.98  (0.77, 1.24) | **FOLFOXIRI + Bevacizumab** |  |  |
| **0.79  (0.68, 0.91)** | **0.75  (0.59, 0.95)** | 0.74  (0.55, 1.01) | 0.97  (0.77, 1.23) | 0.99  (0.80, 1.23) | **FOLFOX + Panitumumab** |  |
| 0.59  (0.29, 1.16) | 0.56  (0.27, 1.13) | 0.56  (0.27, 1.15) | 0.73  (0.36, 1.47) | 0.75  (0.36, 1.47) | 0.75  (0.37, 1.49) | **Pembrolizumab** |
| **Hazard Ratio (95% credible intervals),** **random-effects** | | | | | | |
| **SOC** |  |  |  |  |  |  |
| 1.02  (0.72, 1.38) | **XELOX** |  |  |  |  |  |
| 1.07  (0.74, 1.56) | 1.05  (0.65, 1.80) | **XELOX + Bevacizumab** |  |  |  |  |
| 0.81  (0.61, 1.07) | 0.79  (0.53, 1.27) | 0.76  (0.47, 1.20) | **FOLFOXIRI** |  |  |  |
| **0.77  (0.55, 0.98)** | 0.76  (0.48, 1.14) | 0.72  (0.42, 1.11) | 0.96  (0.60, 1.37) | **FOLFOXIRI + Bevacizumab** |  |  |
| 0.77  (0.54, 1.01) | 0.75  (0.47, 1.18) | 0.72  (0.42, 1.13) | 0.94  (0.60, 1.40) | 0.99  (0.66, 1.56) | **FOLFOX + Panitumumab** |  |
| 0.59  (0.27, 1.32) | 0.58  (0.25, 1.41) | 0.55  (0.23, 1.32) | 0.73  (0.32, 1.71) | 0.76  (0.34, 1.85) | 0.77  (0.34, 1.86) | **Pembrolizumab** |

**Abbreviations**: FOLFOX, 5-fluorouracil + leucovorin + oxaliplatin; FOLFOXIRI, 5-fluorouracil + leucovorin + oxaliplatin + irinotecan; SOC, standard of care; XELOX, oxaliplatin + capecitabine.

**Notes**: Each cell represents the comparison (hazard ratio and 95% credible intervals) of the row treatment versus the column treatment; All bolded values are statistically meaningful at the 0.05 significance level.

Table S13: Estimated constant hazard ratios of overall survival with pembrolizumab versus competing interventions from fixed-effect and random-effects network meta-analysis; adjustment for crossover in KEYNOTE-177 using RPSFT model

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Hazard Ratio (95% credible intervals), fixed-effect** | | | | | | |
| **SOC** |  |  |  |  |  |  |
| 1.05  (0.87, 1.25) | **XELOX** |  |  |  |  |  |
| 1.06  (0.81, 1.37) | 1.01  (0.73, 1.39) | **XELOX + Bevacizumab** |  |  |  |  |
| **0.81  (0.67, 0.97)** | 0.77  (0.60, 1.00) | 0.77  (0.55, 1.06) | **FOLFOXIRI** |  |  |  |
| **0.79  (0.68, 0.93)** | **0.76  (0.60, 0.96)** | 0.75  (0.56, 1.02) | 0.98  (0.77, 1.24) | **FOLFOXIRI + Bevacizumab** |  |  |
| **0.79  (0.68, 0.92)** | **0.75  (0.59, 0.95)** | 0.74  (0.55, 1.01) | 0.97  (0.76, 1.24) | 0.99  (0.80, 1.23) | **FOLFOX + Panitumumab** |  |
| 0.68  (0.41, 1.15) | 0.65  (0.38, 1.13) | 0.64  (0.36, 1.16) | 0.84  (0.48, 1.47) | 0.85  (0.50, 1.47) | 0.86  (0.50, 1.49) | **Pembrolizumab** |
| **Hazard Ratio (95% credible intervals),** **random-effects** | | | | | | |
| **SOC** |  |  |  |  |  |  |
| 1.02  (0.72, 1.36) | **XELOX** |  |  |  |  |  |
| 1.07  (0.74, 1.54) | 1.05  (0.67, 1.77) | **XELOX + Bevacizumab** |  |  |  |  |
| 0.81  (0.61, 1.07) | 0.79  (0.53, 1.26) | 0.76  (0.48, 1.20) | **FOLFOXIRI** |  |  |  |
| **0.77  (0.55, 0.98)** | 0.76  (0.49, 1.13) | 0.73  (0.44, 1.09) | 0.95  (0.61, 1.35) | **FOLFOXIRI + Bevacizumab** |  |  |
| 0.77  (0.54, 1.01) | 0.75  (0.48, 1.17) | 0.72  (0.43, 1.13) | 0.95  (0.60, 1.38) | 0.99  (0.67, 1.53) | **FOLFOX + Panitumumab** |  |
| 0.68  (0.36, 1.29) | 0.67  (0.34, 1.37) | 0.64  (0.31, 1.32) | 0.84  (0.42, 1.68) | 0.89  (0.46, 1.82) | 0.89  (0.45, 1.85) | **Pembrolizumab** |

**Abbreviations**: FOLFOX, 5-fluorouracil + leucovorin + oxaliplatin; FOLFOXIRI, 5-fluorouracil + leucovorin + oxaliplatin + irinotecan; SOC, standard of care; XELOX, oxaliplatin + capecitabine.

**Notes**: Each cell represents the comparison (hazard ratio and 95% credible intervals) of the row treatment versus the column treatment; All bolded values are statistically meaningful at the 0.05 significance level.

Table S14: Estimated constant hazard ratios of progression-free survival with pembrolizumab versus competing interventions from fixed-effect and random-effects network meta-analysis

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Hazard Ratio (95% credible intervals), fixed-effect** | | | | | | |
| **SOC** |  |  |  |  |  |  |
| 1.17  (0.96, 1.43) | **XELOX** |  |  |  |  |  |
| 0.96  (0.65, 1.42) | 0.82  (0.53, 1.26) | **XELOX + Bevacizumab** |  |  |  |  |
| **0.60  (0.47, 0.75)** | **0.51  (0.38, 0.69)** | **0.62  (0.40, 0.97)** | **FOLFOXIRI** |  |  |  |
| **0.70  (0.61, 0.80)** | **0.59  (0.47, 0.76)** | 0.73  (0.48, 1.10) | 1.17  (0.89, 1.53) | **FOLFOXIRI + Bevacizumab** |  |  |
| **0.82  (0.70, 0.95)** | **0.70  (0.55, 0.89)** | 0.85  (0.56, 1.28) | **1.37  (1.05, 1.79)** | 1.17  (0.96, 1.43) | **FOLFOX + Panitumumab** |  |
| **0.60  (0.45, 0.80)** | **0.51  (0.36, 0.72)** | 0.62  (0.38, 1.01) | 1.00  (0.69, 1.45) | 0.86  (0.63, 1.19) | 0.73  (0.53, 1.01) | **Pembrolizumab** |
| **Hazard Ratio (95% credible intervals),** **random-effects** | | | | | | |
| **SOC** |  |  |  |  |  |  |
| 1.17  (0.65, 2.04) | **XELOX** |  |  |  |  |  |
| 0.96  (0.50, 1.85) | 0.82  (0.35, 1.93) | **XELOX + Bevacizumab** |  |  |  |  |
| **0.60  (0.39, 0.92)** | 0.51  (0.25, 1.04) | 0.63  (0.28, 1.33) | **FOLFOXIRI** |  |  |  |
| **0.67  (0.44, 0.88)** | 0.57  (0.28, 1.05) | 0.69  (0.31, 1.37) | 1.11  (0.61, 1.84) | **FOLFOXIRI + Bevacizumab** |  |  |
| 0.82  (0.56, 1.23) | 0.71  (0.36, 1.42) | 0.86  (0.41, 1.84) | 1.38  (0.78, 2.49) | 1.24  (0.79, 2.21) | **FOLFOX + Panitumumab** |  |
| 0.60  (0.33, 1.08) | 0.51  (0.23, 1.19) | 0.62  (0.26, 1.50) | 1.00  (0.48, 2.05) | 0.90  (0.49, 1.89) | 0.73  (0.35, 1.45) | **Pembrolizumab** |

**Abbreviations**: FOLFOX, 5-fluorouracil + leucovorin + oxaliplatin; FOLFOXIRI, 5-fluorouracil + leucovorin + oxaliplatin + irinotecan; SOC, standard of care; XELOX, oxaliplatin + capecitabine.

**Notes**: Each cell represents the comparison (hazard ratio and 95% credible intervals) of the row treatment versus the column treatment; All bolded values are statistically meaningful at the 0.05 significance level.

Table S15: Estimated time-varying hazard ratios of overall survival with pembrolizumab versus competing interventions from random-effect network meta-analysis; adjustment for crossover in KEYNOTE-177 using RPSFT model

| **Mos.** | **Pembrolizumab vs. comparator hazard ratio (95% credible intervals)** | | | | | |
| --- | --- | --- | --- | --- | --- | --- |
| **SOC** | **XELOX** | **XELOX + Bevacizumab** | **FOLFOXIRI** | **FOLFOXIRI**  **+ Bevacizumab** | **FOLFOX + Panitumumab** |
| 4 | 0.92 (0.53, 1.60) | 0.69 (0.36, 1.39) | 0.87 (0.39, 1.86) | 1.38 (0.74, 2.67) | 0.94 (0.49, 1.80) | 1.25 (0.66, 2.48) |
| 8 | 0.78 (0.48, 1.29) | 0.64 (0.36, 1.20) | 0.74 (0.36, 1.45) | 1.13 (0.65, 2.07) | 0.83 (0.46, 1.50) | 1.04 (0.59, 1.95) |
| 12 | 0.67 (0.42, 1.08) | 0.59 (0.34, 1.09) | 0.63 (0.33, 1.17) | 0.93 (0.54, 1.66) | 0.74 (0.42, 1.29) | 0.87 (0.51, 1.59) |
| 16 | **0.57 (0.34, 0.95)** | 0.55 (0.31, 1.02) | 0.53 (0.28, 1.00) | 0.76 (0.44, 1.39) | 0.65 (0.36, 1.17) | 0.72 (0.41, 1.35) |
| 20 | **0.49 (0.27, 0.88)** | 0.51 (0.27, 1.01) | **0.45 (0.23, 0.89)** | 0.63 (0.34, 1.22) | 0.58 (0.30, 1.10) | 0.61 (0.32, 1.20) |
| 24 | **0.41 (0.21, 0.83)** | 0.48 (0.22, 1.04) | **0.38 (0.18, 0.83)** | 0.52 (0.25, 1.10) | 0.51 (0.24, 1.08) | 0.51 (0.24, 1.10) |
| 28 | **0.35 (0.16, 0.79)** | 0.44 (0.18, 1.09) | **0.33 (0.13, 0.80)** | 0.42 (0.18, 1.01) | 0.45 (0.19, 1.07) | 0.42 (0.17, 1.03) |
| 32 | **0.30 (0.12, 0.77)** | 0.41 (0.15, 1.16) | **0.28 (0.10, 0.79)** | **0.35 (0.13, 0.94)** | 0.40 (0.15, 1.07) | **0.35 (0.13, 0.98)** |
| 36 | **0.26 (0.09, 0.75)** | 0.38 (0.12, 1.25) | **0.24 (0.07, 0.78)** | **0.29 (0.09, 0.88)** | 0.35 (0.11, 1.10) | **0.29 (0.09, 0.93)** |
| 40 | **0.22 (0.06, 0.74)** | 0.36 (0.09, 1.35) | **0.20 (0.05, 0.77)** | **0.24 (0.07, 0.83)** | 0.31 (0.09, 1.11) | **0.24 (0.07, 0.90)** |
| 44 | **0.19 (0.05, 0.72)** | 0.33 (0.07, 1.46) | **0.17 (0.04, 0.77)** | **0.19 (0.05, 0.79)** | 0.28 (0.07, 1.15) | **0.20 (0.05, 0.87)** |
| 48 | **0.16 (0.04, 0.71)** | 0.31 (0.06, 1.59) | **0.14 (0.03, 0.78)** | **0.16 (0.03, 0.75)** | 0.25 (0.05, 1.18) | **0.17 (0.03, 0.84)** |

**Abbreviations**: FOLFOX, 5-fluorouracil + leucovorin + oxaliplatin; FOLFOXIRI, 5-fluorouracil + leucovorin + oxaliplatin + irinotecan; SOC, standard of care; XELOX, oxaliplatin + capecitabine.

**Notes**: Model presented is P1=1, P2=0 (scale and 1st shape); All bolded values are statistically significant at the 0.05 significance level.

Table S16: Odds ratios estimated from fixed-effect network meta-analysis for treatment-related Grade 3+ adverse events

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Odds ratios (95% credible intervals)** | | | | | |
| **SOC** |  | | | | |
| **2.23  (1.11, 4.68)** | **XELOX** |  | | | |
| 1.32  (0.92, 1.91) | 0.59  (0.26, 1.30) | **XELOX + Bevacizumab** |  | | |
| **1.75  (1.10, 2.86)** | 0.79  (0.32, 1.86) | 1.33  (0.72, 2.44) | **FOLFOXIRI + Bevacizumab** |  | |
| **2.69  (1.89, 3.85)** | 1.21  (0.53, 2.68) | **2.03  (1.22, 3.41)** | 1.53  (0.84, 2.75) | **FOLFOX + Panitumumab** |  |
| **0.14  (0.08, 0.24)** | **0.06  (0.03, 0.15)** | **0.11  (0.06, 0.20)** | **0.08  (0.04, 0.16)** | **0.05  (0.03, 0.10)** | **Pembrolizumab** |

**Abbreviations**: FOLFOX, 5-fluorouracil + leucovorin + oxaliplatin; FOLFOXIRI, 5-fluorouracil + leucovorin + oxaliplatin + irinotecan; SOC, standard of care; XELOX, oxaliplatin + capecitabine.

**Notes**: Each cell represents the comparison (odds ratio and 95% credible intervals) of the row treatment versus the column treatment; All bolded values are statistically meaningful at the 0.05 significance level.

References

1. Sung H, Ferlay J, Siegel RL *et al*. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries*.* *CA: A Cancer Journal for Clinicians* 71(3), 209-249 (2021).

2. Biller LH, Schrag D. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review*.* *JAMA* 325(7), 669-685 (2021).

3. Punt CJA, Koopman M, Vermeulen L. From tumour heterogeneity to advances in precision treatment of colorectal cancer*.* *Nature Reviews Clinical Oncology* 14(4), 235-246 (2017).

4. Van Cutsem E, Cervantes A, Adam R *et al*. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer*.* *Annals of Oncology* 27(8), 1386-1422 (2016).

5. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Colon Cancer V.3.2021. © National Comprehensive Cancer Network, Inc. (September 21, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.).

6. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Rectal Cancer V.2.2021. © National Comprehensive Cancer Network, Inc. (September 27, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.).

7. Kurzawski G, Suchy J, Debniak T, Kładny J, Lubiński J. Importance of microsatellite instability (MSI) in colorectal cancer: MSI as a diagnostic tool*.* *Annals of Oncology* 15(Suppl 4), iv283-284 (2004).

8. Phipps AI, Limburg PJ, Baron JA *et al*. Association between molecular subtypes of colorectal cancer and patient survival*.* *Gastroenterology* 148(1), 77-87.e72 (2015).

9. Le Dung T, Durham Jennifer N, Smith Kellie N *et al*. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade*.* *Science* 357(6349), 409-413 (2017).

10. Le DT, Uram JN, Wang H *et al*. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency*.* *New England Journal of Medicine* 372(26), 2509-2520 (2015).

11. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication> (Sep 21).

12. André T, Shiu K-K, Kim TW *et al*. Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer*.* *New England Journal of Medicine* 383(23), 2207-2218 (2020). \*\* Pivotal RCT of pembrolizumab in the population of interest

13. Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) <https://clinicaltrials.gov/ct2/show/NCT02563002>

14. Pembrolizumab Doubles Progression-Free Survival in MSI-H/dMMR Metastatic Colorectal Cancer <https://www.ascopost.com/issues/june-10-2020/pembrolizumab-doubles-progression-free-survival-in-msi-hdmmr-metastatic-colorectal-cancer>

15. FDA approves pembrolizumab for first-line treatment of MSI-H/dMMR colorectal cancer <https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-first-line-treatment-msi-hdmmr-colorectal-cancer> (Sep 21).

16. Trullas A, Delgado J, Genazzani A *et al*. The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer*.* *ESMO Open* 6(3), 100-145 (2021).

17. Summary of opinion (post authorisation) Keytruda pembrolizumab <https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda-ii-91_en.pdf> (Sep 21).

18. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials*.* *Medical decision making* 33(5), 641-656 (2013).

19. Jansen JP, Naci H. Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers*.* *BMC Medicine* 11(1), 1-8 (2013).

20. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement*.* *J Clin Epidemiol* 62(10), 1006-1012 (2009).

21. Higgins JP, Thomas J, Chandler J *et al*. *Cochrane handbook for systematic reviews of interventions*. John Wiley & Sons, (2019).

22. Risk of Bias 2 (RoB 2) tool <https://methods.cochrane.org/risk-bias-2> (Sep 30).

23. Jansen JP, Cope S. Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes*.* *BMC medical research methodology* 12(1), 152-152 (2012).

24. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis*.* *Statistics in medicine* 29(7-8), 932-944 (2010).

25. Latimer NR, Abrams KR, Lambert PC *et al*. Adjusting for treatment switching in randomised controlled trials – A simulation study and a simplified two-stage method*.* *Statistical Methods in Medical Research* 26(2), 724-751 (2014).

26. Robins JM, Tsiatis AA. Correcting for non-compliance in randomized trials using rank preserving structural failure time models*.* *Communications in Statistics - Theory and Methods* 20(8), 2609-2631 (1991).

27. Jansen JP. Network meta-analysis of survival data with fractional polynomials*.* *BMC Med Res Methodol* 11(1), 1-14 (2011). \*\* Methods for conducting an NMA in the presence of non-proportional hazards

28. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals*.* *Biometrika* 81(3), 515-526 (1994).

29. Dias S, Welton NJ, Sutton AJ, Ades AE. *NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials*. National Institute for Health and Clinical Excellence, (2011).

30. Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence Synthesis for Decision Making 2: A Generalized Linear Modeling Framework for Pairwise and Network Meta-analysis of Randomized Controlled Trials*.* *Medical Decision Making* 33(5), 607-617 (2013).

31. Ouwens MJNM, Philips Z, Jansen JP. Network meta-analysis of parametric survival curves*.* *Research Synthesis Methods* 1(3-4), 258-271 (2011).

32. Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves*.* *BMC Med Res Methodol* 12 9 (2012).

33. Dempster AP. The direct use of likelihood for significance testing*.* *Statistics and Computing* 7(4), 247-252 (1997).

34. Plummer M. JAGS: A program for analysis of Bayesian graphical models using Gibbs sampling*.* *Proceedings of the 3rd international workshop on distributed statistical computing* 124(125.10), 1-10 (2003).

35. Muller CI, Schulmann K, Reinacher-Schick A *et al*. Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group*.* *Int J Colorectal Dis* 23(11), 1033-1039 (2008).

36. Simkens LH, Van Tinteren H, May A *et al*. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group*.* *Lancet* 385(9980), 1843-1852 (2015).

37. Goey KKH, Elias SG, Van Tinteren H *et al*. Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: Updated results and molecular subgroup analyses of the phase 3 CAIRO3 study*.* *Annals of Oncology* 28(9), 2128-2134 (2017).

38. Porschen R, Arkenau HT, Kubicka S *et al*. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group*.* *J Clin Oncol* 25(27), 4217-4223 (2007).

39. Cassidy J, Clarke S, Diaz-Rubio E *et al*. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results*.* *Br J Cancer* 105(1), 58-64 (2011).

40. Personeni N, Rimassa L, Verusio C *et al*. Prognostic factors in KRAS wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with biweekly cetuximab (C) plus irinotecan, fluorouracil, and leucovorin (FOLFIRI): A phase II study*.* *J Clin Oncol* 31(15 SUPPL. 1), (2013).

41. Madajewicz S, Waterhouse DM, Ritch PS *et al*. Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer*.* *Invest New Drugs* 30(2), 772-778 (2012).

42. Tournigand C, Chibaudel B, Samson B *et al*. Improving safety in first-line metastatic colorectal cancer (MCRC) therapy with bevacizumab: Modified FOLFOX7 versus XELOX2—Results of the induction phase of the GERCOR DREAM randomized phase III study*.* *J Clin Oncol* 33(3\_suppl), 670-670 (2015).

43. Kato S, Imai H, Gamoh M *et al*. Intermittent Withdrawal of Oxaliplatin for Alleviating Neurotoxicity during Oxaliplatin-Based Chemotherapy for Japanese Patients with Inoperable or Metastatic Colorectal Cancer: A Phase 2 Multicenter Study*.* *Tohoku J Exp Med* 245(1), 21-28 (2018).

44. Schmoll H, Garlipp B, Junghanss C *et al*. FOLFOX/Bevacizumab (Beva) +/-Irinotecan in advanced colorectal cancer (CRC): a randomized phase II trial (AIO KRK 0209, CHARTA)*.* *Annals of Oncology* 27 (2016).

45. Hans-Joachim S, Benjamin G, Christian J *et al*. FOLFOX/Bevacizumab 1/2 Irinotecan in advanced colorectal cancer (AIO) "cHARTA": final results and multivariate prognostic factor analysis*.* *Annals of Oncology* 28 (2017).

46. Meinert F, Cygon F, Stein A *et al*. CHARTA: fOLFOX/Bevacizumab +/- Irinotecan in advanced colorectal cancer; a multivariate analysis of prognostic and predictive factors*.* *Oncology research and treatment* 40(162), (2017).

47. Meinert F, Schmoll H, Garlipp B *et al*. CHARTA: fOLFOX/Bevacizumab+/-irinotecan in advanced colorectal cancer-long term outcome*.* *Oncology research and treatment* 41(245), (2018).

48. Schmoll H, Garlipp B, Junghanss C *et al*. CHARTA: fOLFOX+bevacizumab +/- irinotecan in advanced colorectal cancer (CRC)- Final results of the randomized phase II trial of the AIO (KRK 0209)*.* *J Clin Oncol.* 35(4 Supplement 1), (2017).

49. Stein A, Meinert F, Cygon F *et al*. "CHARTA" - FOLFOX/Bevacicumab vs. FOLFOXIRI/Bevacicumab in advanced colorectal cancer - Final results, prognostic and potentially predictive factors from the randomized Phase II trial of the AIO*.* *Oncology research and treatment* 41(9), (2018).

50. Goring S, Jansen JP. PNS308 METHODOLOGICAL APPROACHES FOR INCORPORATING INVESTIGATORS' CHOICE COMPARATOR ARMS INTO NETWORK META-ANALYSES*.* *Value in Health* 22, S815-S816 (2019). \* Methods for accounting for investigators’ choice arms in NMA

51. Van Cutsem E, Kohne CH, Hitre E *et al*. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer*.* *New England Journal of Medicine* 360(14), 1408-1417 (2009).

52. Van Cutsem E, Kohne CH, Lang I *et al*. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status*.* *J Clin Oncol* 29(15), 2011-2019 (2011).

53. Bokemeyer C, Van Cutsem E, Rougier P *et al*. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials*.* *Eur J Cancer* 48(10), 1466-1475 (2012).

54. Anonymous. Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer*.* *Clinical Advances in Hematology and Oncology* 8(3), 7-8 (2010).

55. Guren TK, Thomsen M, Kure EH *et al*. Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study*.* *Br J Cancer* 116(10), 1271-1278 (2017).

56. Tveit KM, Guren T, Glimelius B *et al*. Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: The NORDIC VII study (NCT00145314), by the Nordic Colorectal Cancer Biomodulation Group*.* *J Clin Oncol* 29(4 SUPPL. 1), (2011).

57. Tveit KM, Guren T, Glimelius B *et al*. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study*.* *J Clin Oncol* 30(15), 1755-1762 (2012).

58. Bokemeyer C, Bondarenko I, Hartmann JT *et al*. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study*.* *Annals of Oncology* 22(7), 1535-1546 (2011).

59. Bokemeyer C, Bondarenko I, Makhson A *et al*. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer*.* *J Clin Oncol* 27(5), 663-671 (2009).

60. Bokemeyer C, Kohne CH, Ciardiello F *et al*. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer*.* *Eur J Cancer* 51(10), 1243-1252 (2015).

61. Qin S, Li J, Wang L *et al*. Efficacy and tolerability of first-line cetuximab plus leucovorin, fluorouracil, and oxaliplatin (FOLFOX-4) versus FOLFOX-4 in patientswith RASwild-typemetastatic colorectal cancer: The open-label, randomized, phase III TAILOR trial*.* *J Clin Oncol* 36(30), 3031-3039 (2018).

62. Qin S, Guo W, Xu JM *et al*. Final overall survival (OS) analysis of first-line (1L) FOLFOX-4 +/- cetuximab (cet) in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 3 TAILOR trial*.* *J Clin Oncol* 36(15), (2018).

63. Qin S, Xu J, Wang L *et al*. First-line FOLFOX-4 +/- cetuximab in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC): the open-label, randomized phase 3 TAILOR trial*.* *Annals of Oncology* 27 (2016).

64. Qin S, Xu J, Wang L *et al*. Impact of tumor epidermal growth factor receptor (EGFR) status on the outcomes of first-line FOLFOX-4 +/- cetuximab in patients (pts) with RAS-wild-type (wt) metastatic colorectal cancer (mCRC) in the randomized phase 3 TAILOR trial*.* *Annals of Oncology* 27 (2016).

65. Xu J, Ye LC, Ren L, Wei Y. A randomized, controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases*.* *Annals of Oncology* 23 (2012).

66. Ye LC, Zhu D, Ren L *et al*. Tumor response and secondary resectability of colorectal liver metastases following cetuximab with chemotherapy: a randomized, controlled study*.* *Annals of Oncology* 23 (2012).

67. Ye LC, Liu TS, Ren L *et al*. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases*.* *J Clin Oncol* 31(16), 1931-1938 (2013).

68. Innocenti F, Ou FS, Qu X *et al*. Mutational analysis of patients with colorectal cancer in CALGB/SWOG 80405 identifies new roles of microsatellite instability and tumor mutational burden for patient outcome*.* *J Clin Oncol* 37(14), 1217-1227 (2019).

69. Lenz HJ, Ou FS, Venook AP *et al*. Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance)*.* *J Clin Oncol* 37(22), 1876 (2019).

70. Venook AP, Niedzwiecki D, Lenz HJ *et al*. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial*.* *JAMA* 317(23), 2392-2401 (2017).

71. Uetake H, Emi Y, Yamanaka T *et al*. A randomized phase II study of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab for previously untreated, liverlimited metastatic colorectal cancer that is unsuitable for resection (ATOM trial)*.* *J Clin Oncol* 36(4), (2018).

72. Oki E, Emi Y, Yamanaka T *et al*. Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)*.* *Br J Cancer* 121(3), 222-229 (2019).

73. Heinemann V, Von Weikersthal LF, Decker T *et al*. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial*.* *Lancet Oncol* 15(10), 1065-1075 (2014).

74. Modest DP, Von Weikersthal LF, Stintzing S *et al*. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (fire-3)*.* *Annals of Oncology* 24, pp.iv22-iv23 (2013).

75. Stintzing S, Fischer Von Weikersthal L, Decker T *et al*. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306*.* *Annals of Oncology* 23(7), 1693-1699 (2012).

76. Stintzing S, Modest DP, Rossius L *et al*. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial*.* *Lancet Oncol* 17(10), 1426-1434 (2016).

77. Stintzing S, Jung A, Rossius L *et al*. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients*.* *Eur J Cancer* 49, pp.S8-S9 (2013).

78. Stintzing S, Jung A, Rossius L *et al*. Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3-A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients*.* *J Clin Oncol* 32(3 SUPPL. 1), (2014).

79. Guan ZZ, Xu JM, Luo RC *et al*. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial*.* *Chinese journal of cancer* 30(10), 682-689 (2011).

80. Hurwitz H, Fehrenbacher L, Novotny W *et al*. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer*.* *New England Journal of Medicine* 350(23), 2335-2342 (2004).

81. Hurwitz H, Fehrenbacher L, Novotny W. Bevacizumab in combination with irinotecan plus fluorouracil plus leucovorin chemotherapy prolongs survival but increases adverse events in people with metastatic colorectal cancer*.* *Cancer Treatment Reviews* 30(8), 715-720 (2004).

82. Hurwitz HI, Yi J, Ince W, Novotny WF, Rosen O. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer*.* *Oncologist* 14(1), 22-28 (2009).

83. Passardi A, Nanni O, Tassinari D *et al*. Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial*.* *Annals of Oncology* 26(6), 1201-1207 (2015).

84. Stathopoulos GP, Batziou C, Trafalis D *et al*. Treatment of colorectal cancer with and without bevacizumab: a phase III study*.* *Oncology* 78(5-6), 376-381 (2010).

85. Falcone A, Ricci S, Brunetti I *et al*. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest*.* *J Clin Oncol* 25(13), 1670-1676 (2007).

86. Masi G, Vasile E, Loupakis F *et al*. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis*.* *J Natl Cancer Inst* 103(1), 21-30 (2011).

87. Maiello E, Di Maggio G, Cordio S *et al*. Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802)*.* *Clinical Colorectal Cancer* 19(2), 109-115 (2020).

88. Maiello E, Di Maggio G, Cordio S *et al*. Bevacizumab (B) + bi-weekly capecitabine (C) and oxaliplatin (O) (XELOX2) or FOLFOX4 in first-line treatment of metastatic colorectal cancer (mCRC): final results of a multicenter randomized phase II trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM protocol 2802)*.* *J Clin Oncol* 36(15), (2018).

89. Andre T, Shiu K-K, Kim TW *et al*. Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study*.* *J Clin Oncol* 38(18\_suppl), LBA4-LBA4 (2020).

90. Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA. A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)*.* *Clinical Study Report*  (2020).

91. Ychou M, Rivoire M, Thezenas S *et al*. A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial*.* *Ann Surg Oncol* 20(13), 4289-4297 (2013).

92. Gruenberger T, Bridgewater J, Chau I *et al*. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial*.* *Annals of Oncology* 26(4), 702-708 (2015).

93. Schwartzberg L, Rivera F, Karthaus M *et al*. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer*.* *J Clin Oncol* 32(21), 2240-2247 (2014).

94. Karthaus M, Schwartzberg L, Rivera F *et al*. Updated overall survival (OS) analysis of novel predictive KRAS/NRAS mutations beyond KRAS exon 2 in PEAK: A 1st-line phase 2 study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) in metastatic colorectal cancer (mCRC)*.* *Eur J Cancer* 49, pp.S516 (2013).

95. Rivera F, Karthaus M, Hecht JR *et al*. Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma*.* *Int J Colorectal Dis* 32(8), 1179-1190 (2017).

96. Bennett L, Zhao Z, Barber B *et al*. Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment*.* *Br J Cancer* 105(10), 1495-1502 (2011).

97. Douillard J, Siena S, Cassidy J *et al*. Final results from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first line metastatic colorectal cancer (mCRC)*.* *J Clin Oncol* 29(15 SUPPL. 1), (2011).

98. Douillard JY, Siena S, Cassidy J *et al*. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer*.* *Annals of Oncology* 25(7), 1346-1355 (2014).

99. Douillard JY, Siena S, Cassidy J *et al*. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study*.* *J Clin Oncol* 28(31), 4697-4705 (2010).

100. Udar N, Lofton-Day C, Dong J *et al*. Clinical validation of the next-generation sequencing-based Extended RAS Panel assay using metastatic colorectal cancer patient samples from the phase 3 PRIME study*.* *J Cancer Res Clin Oncol* 144(10), 2001-2010 (2018).

101. Peeters M, Douillard JY, Siena S *et al*. Impact of post-protocol anti-epidermal growth factor receptor therapy on survival in wild-type KRAS/NRAS metastatic colorectal cancer: Data from the PRIME study*.* *Eur J Cancer* 49, pp.S17 (2013).

102. Anonymous. Panitumumab with FOLFOX4 compared to FOLFOX4 alone as first-line treatment in metastatic colorectal cancer*.* *Clinical Advances in Hematology and Oncology* 8(3), 9-10 (2010).

103. Souglakos J, Androulakis N, Syrigos K *et al*. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)*.* *Br J Cancer* 94(6), 798-805 (2006).

104. Vamvakas L, Athanasiadis A, Karampeazis A *et al*. Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG)*.* *Critical Reviews in Oncology/Hematology* 76(1), 61-70 (2010).

105. Hochster HS, Hart LL, Ramanathan RK *et al*. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study*.* *J Clin Oncol* 26(21), 3523-3529 (2008).

106. Falcone A, Cremolini C, Masi G *et al*. FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group*.* *J Clin Oncol* 31(15), 3505-3505 (2013).

107. Loupakis F, Cremolini C, Masi G *et al*. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer*.* *New England Journal of Medicine* 371(17), 1609-1618 (2014).

108. Cremolini C, Loupakis F, Masi G *et al*. Folfoxiri/bevacizumab versus folfiri/ bevacizumab as first-line treatment in unresectable metastatic colorectal cancer: Results of phase iii tribe trial by gono group*.* *Annals of Oncology* 24, 21 (2013).

109. Cremolini C, Loupakis F, Antoniotti C *et al*. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest*.* *Annals of Oncology* 26(6), 1188-1194 (2015).

110. Cremolini C, Loupakis F, Lonardi S *et al*. Subgroup analyses in RAS mutant, BRAF mutant and "allwt" metastatic colorectal cancer patients treated with folfoxiri plus bevacizumab (BEV) or folfiri plus BEV in the tribe study*.* *Annals of Oncology* 25 (2014).

111. Cremolini C, Loupakis F, Antoniotti C *et al*. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial treatment for metastatic colorectal cancer (TRIBE study): Updated survival results and final molecular subgroups analyses*.* *Annals of Oncology* 26, pp.iv109 (2015).

112. Sastre J, Vieitez JM, Gomez-España MA *et al*. Randomized phase III study comparing FOLFOX+ bevacizumab versus folfoxiri+ bevacizumab (BEV) as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with≥ 3 baseline circulating tumor cells (bCTCs)*.* *J Clin Oncol* 37(15\_suppl), 3507-3507 (2019).

113. Cohen R, Pudlarz T, Delattre J-F, Colle R, André T. Molecular Targets for the Treatment of Metastatic Colorectal Cancer*.* *Cancers* 12(9), (2020). \* Highlights recent trends in the clinical management of mCRC which focus on using predictive biomarkers

114. Lai E, Liscia N, Donisi C *et al*. Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer*.* *Cancers* 12(5), (2020).

115. Benson AB, Venook AP, Al-Hawary MM *et al*. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology*.* *Journal of the National Comprehensive Cancer Network J Natl Compr Canc Netw* 19(3), 329-359 (2021).

116. Zhao P, Li L, Jiang X, Li Q. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy*.* *Journal of Hematology & Oncology* 12(1), 54 (2019). \* Highlights the potential benefits of immunotherapies among MSI-H/dMMR patients

117. Calu V, Ionescu A, Stanca L *et al*. Key biomarkers within the colorectal cancer related inflammatory microenvironment*.* *Scientific Reports* 11(1), 7940 (2021).

118. Hameed Y, Usman M, Liang S, Ejaz S. Novel diagnostic and prognostic biomarkers of colorectal cancer: Capable to overcome the heterogeneity-specific barrier and valid for global applications*.* *PLOS ONE* 16(9), e0256020 (2021). \*Discusses potential future trends in CRC management based on biomarkers.